


NHC-Cu(I)-Catalyzed Friedländer-Type Annulation of Fluorinated *o*-Aminophenones with Alkynes on Water: Competitive Base-Catalyzed Dibenzo[*b,f*][1,5]diazocine Formation

Paweł Czerwiński and Michał Michalak*^{ID}

Institute of Organic Chemistry, Polish Academy of Sciences, Kasprzaka 44/52, 01-224 Warsaw, Poland

Supporting Information

ABSTRACT: An efficient, easily scalable synthesis of 4-trifluoromethylquinolines and naphthydrines (as well as their difluoro- and perfluoro-analogues) as a result of tandem direct catalytic alkylation/dehydrative condensation of *o*-amino-fluoromethylketones (*o*-FMKs), for the first time catalyzed by NHC-copper(I) complexes on water, is reported. A wide range of terminal alkynes is tolerated under the reaction conditions, including β -lactam-, steroid-, and sugar-derived ones, leading to desired quinolines and naphthydrines with good yields. Further investigations proved that *o*-FMKs could be efficiently transformed into a rare class of heterocyclic compounds—dibenzo[*b,f*][1,5]diazocines—by a base-catalyzed condensation, also on water. The developed method was applied for gram-scale synthesis of a fluorinated analogue of G protein-coupled receptor antagonist (GPR91).



INTRODUCTION

Fluorine-containing organic molecules, in particular fluorinated heterocycles, constitute a privileged structural motif in many areas of modern society, including material science, pharmaceutical industry, agrochemicals, fine chemicals,¹ and most of all medicinal chemistry.² More than 30% of all compounds present on the worldwide agrochemical and pharmaceutical market contain fluorine or fluorinated groups.^{1b,3} The incorporation of fluorine into organic compounds strongly affects their biological properties, simultaneously allowing for structural elaboration, and hence has become crucial for modern drug development. It is well-established that the presence of fluorine improves bioavailability and increases lipophilicity and metabolic stability.^{2,3b,4} Iconic examples of the beneficial properties bestowed upon fluorinated compounds are Ezetimibe⁵ (inhibitor of cholesterol adsorption) and Efavirenz⁶ (non-nucleoside inhibitor of reverse transcriptase of HIV), which have been commercialized in the past decade.

Among a plethora of fluorinated heterocycles, quinolines and quinolones have retained long-standing interest of the synthetic community. Tremendous advances in the field of fluorination⁷ have naturally led to the discovery of fluorinated quinolines or quinolones exhibiting remarkable biological properties, and some of them have been introduced to the pharmaceutical market. Representative examples include fluoroquine and mefloquine (antimalarial drugs), brequinar (used in transplantation and for the treatment of psoriasis and rheumatic arthritis), flosequinan (used for the treatment of heart disease) and many derivatives of fluoroquinolones with a broad spectrum of antibacterial activity (Figure 1).⁸

Due to the importance of quinolines in natural product synthesis and medicinal chemistry, many useful methods for their preparation have been developed to date. Among classical methods leading to this heterocyclic scaffold, including the




Figure 1. Representative structures of biologically active fluorine-containing quinolines and quinolones.

Skraup reaction,⁹ the Doebner–von Miller reaction,¹⁰ the Gould–Jacobs reaction,¹¹ the Conrad–Limpach reaction,¹² the Combes synthesis,¹³ the Knorr synthesis,¹⁴ and the Nientowski synthesis,¹⁵ the Friedländer reaction¹⁶ constitutes an obvious choice due to its simplicity. Generally, the classical protocol for the latter involves an acid- or a base-catalyzed reaction between a 2-aminocarbonyl compound with an α -methylene ketone. However, in most cases high temperature is required.^{16b} To avoid harsh conditions and expand the scope of substrates in terms of functional group compatibility, an alternative route based on tandem addition of terminal alkynes to 2-aminobenzaldehydes and spontaneous cyclization has been developed and serves as an excellent alternative. Gold(I) complexes¹⁷ have most often been used as

Received: May 19, 2017

Published: July 7, 2017


catalysts, in addition to sparse reports devoted to silver(I),¹⁸ iron(III),¹⁹ and copper salts (which necessitate the preactivation of the carbonyl group via an iminium ion).²⁰ In this respect, the application of *o*-aminotrifluoromethylketones (*o*-TFMKs) for the synthesis of fluorinated quinolines is largely unexplored. To date, the application of a stoichiometric amount of Zn(OTf)₂²¹ and catalytic pyrophoric Ag/PCy₃²² have been reported with an extremely narrow scope of substrates.

Herein, we present the first application of *N*-heterocyclic carbene copper(I) complexes (NHCCuX) as efficient catalysts (2 mol %) for the synthesis of fluorine-containing quinolines (CF₃, CF₂H, CnF_{2n+1}) and naphthyridines via direct catalytic alkylation/dehydrative cyclization sequence on water (Friedländer-type reaction). Recently, we have proved the effectiveness of *N*-heterocyclic carbene copper(I) complexes in direct catalytic alkylation of chiral nitrones²³ and trifluoromethylketones²⁴ (TFMKs) on water (Scheme 1). The key rationale


Scheme 1. Direct Catalytic Alkylation of Different Electrophiles on Water Catalyzed by NHCCuX Complexes

Our previous studies

A. Diastereoselective alkylation of chiral nitrones



B. Direct catalytic alkylation of trifluoromethylketones



This study



R = alkyl, aryl, halogen, EDG, EWG


for a successful transformation was based on the observation that NHC-copper(I) complexes can form stable, monomeric (as confirmed by X-ray crystallography²⁵), stable, highly reactive (e.g., in triazole formation²⁶) and moisture-insensitive acetylides, in contrast to polymeric ones, generated from copper(I) salts themselves.²⁷ Moreover, strong σ -donor properties of the NHC ligands enhance the nucleophilicity of the C_{sp} carbon atom of the acetylide, facilitating the addition to the electrophile.²⁸ Bearing in mind the successful application of

NHCCuX complexes for the alkylation of nitrones and TFMKs, we anticipated that the same catalytic system, namely NHCCuX/water, should deliver a practical route to fluorinated quinolines as a result of direct catalytic alkylation/dehydrative cyclization sequence.

RESULTS AND DISCUSSION

At the outset of our study, we selected the reaction of cyclopropylacetylene (**2a**) with *o*-TFMK **1a** (Scheme 2). First,

Scheme 2. Model Reaction



we examined the effect of solvent on the model reaction. When substrates were mixed together in common organic solvents (Table 1, entry 1) in the presence of 2 mol % IPrCuCl and 20 mol % of Et₃N, only unreacted starting materials were detected, even after 48 h at 50 °C. However, when EtOH was used, the expected quinoline **3a** was isolated with poor 10% yield after chromatography (Table 1, entry 2). The best 42% yield was obtained when the reaction was conducted in a mixture of water and DME (v/v 20:1)²⁹ at a higher temperature, which is consistent with our previous findings.^{23,24} Surprisingly, dibenzo[*b,f*][1,5]diazocine **4a** was also isolated as a byproduct with 43% yield. In order to improve the yield of quinoline **3a**, we screened carefully the influence of the type and the amount of base. After some experimentation, it was found that the yield of quinoline **3a** could be improved to 61% when 2 mol % of 1,1,3,3-tetramethylguanidine (TMG) were used. Dibenzo[*b,f*][1,5]diazocine **4a** was isolated with 21% yield in this case. These results clearly suggested that the formation of dibenzo[*b,f*][1,5]diazocine **4a** is a base-catalyzed process and its formation can be suppressed by lowering the loading of TMG to an equimolar amount relative to the NHCCuX complex used.

To the best of our knowledge, this is the first example of a base-catalyzed synthesis of a dibenzo[*b,f*][1,5]diazocine on water. Similar compounds have been reported as byproducts by Wang³⁰ during the synthesis of quinolines via the Friedländer reaction and by Warm³¹ in an attempt toward the large-scale preparation of efavirenz. To confirm the base-catalyzed mechanism, ketones **1** were treated with 20 mol % of TMG on water, furnishing heterocycles **4a** and **4b** cleanly in 66% and

Table 1. Initial Optimization of the Reaction Conditions^a

entry	base (mol %)	solvent	temperature (°C)	reaction time (h)	yield of 3a (%) ^b	yield of 4a (%) ^b
1	Et ₃ N (20)	DME, DCE, toluene, DMF, DMSO, pyridine	50	48	–	–
2	Et ₃ N (20)	EtOH	50	48	10	n.d.
3	Et ₃ N (20)	H ₂ O/DME (20/1)	50	48	23	22
4	Et ₃ N (20)	H ₂ O/DME (20/1)	100	16	42	43
5	TMG (20)	H ₂ O/DME (20/1)	100	16	53	15
6	TMG (2)	H ₂ O/DME (20/1)	100	16	55	26
7	TMG (2)	H ₂ O/DME (20/1)	100	16	61	21

^aReaction conditions: ketone **1a** (1.0 mmol), alkyne **2a** (1.2 mmol), NHCCuX (0.02 mmol), tetradecane (10 μ L), DME (0.1 mL), H₂O (2 mL) and appropriate amount of base; conversion was based on GC with tetradecane as internal standard. ^bIsolated yield after chromatography; n.d., not determined; TMG, 1,1,3,3-Tetramethylguanidine.

58% yield, respectively (Scheme 3). Inquiries into the scope of formation of dibenzo[*b,f*][1,5]diazocines of type 4 are underway with promising results.

Scheme 3. TMG-Catalyzed Formation of Dibenzo[*b,f*][1,5]diazocine 4



This unprecedented product distribution led us to examine the influence of the electronic and steric nature of the NHC carbene-copper(I) complex in more detail (for the structures of NHC complexes used, see Figure 2). Initially, we were pleased




Figure 2. NHC metal complexes used for quinoline 3a formation.

to find that copper(I) complexes bearing IMes or SIMes carbene ligands also catalyze the formation of quinoline 3a. However, no clear conclusion could be given regarding the role of counterion in the copper complex (Table 2, entries 1–4). Quinoline 3a was isolated with moderate to high yields. In a series of more hindered unsaturated IPr or SIPr complexes, the yield of the reaction could be slightly improved by changing the counterion from iodide or chloride to bromide (Table 2, entry 6 and 9). Unfortunately, in all cases dibenzo[*b,f*][1,5]diazocine 4a was also formed in significant quantities, up to 32%. Unexpectedly, dibenzo[*b,f*][1,5]diazocine 4a was isolated in higher yield when the reaction was catalyzed by homoleptic ionic [ICy]₂CuBF₄. Other ionic complexes were less effective. The best results in terms of conversion and yield were obtained when sterically hindered complex IPr*CuCl was applied. Quinoline 3a was isolated in 71% yield while dibenzo[*b,f*]-[1,5]diazocine was formed in low 7% yield (Table 2, Entry 15). Pleasingly, the same reaction conducted on 5.0 mmol scale furnished cleanly product in 76% after chromatography (more than 1 g of 3a was isolated, Table 2, entry 16).


With the optimized conditions (2 mol % of IPr*CuCl and 2 mol % of TMG on water) in hand, we explored the scope of alkynes. It was found that phenylacetylene and its derivatives afforded products 3b–e with good yields when electron-donating substituents were present, while electron-withdrawing groups such as CF₃ gave poor yields (Scheme 4, 3i). Further investigations revealed that heterocyclic substituents were

Table 2. Influence of the NHC Carbene Ligand and the Counterion on the Alkynylation/Cyclization Sequence Leading to Quinoline 3a and Diazocine 4a

entry	NHCCuX (2 mol %)	conversion (%) ^a	quinoline 3a (%) ^{b,c}	diazocine 4a (%) ^{b,c}
1	IMesCuCl	94	42 (48)	39 (40)
2	IMesCuBr	91	51 (57)	28 (28)
3	SIMesCuCl	95	35 (45)	40 (40)
4	SIMesCuBr	91	33 (44)	35 (41)
5	IPrCuCl	91	44 (50)	16 (22)
6	IPrCuBr	92	46 (53)	31 (34)
7	IPrCuI	90	37 (45)	32 (33)
8	SIPrCuCl	87	32 (49)	22 (27)
9	SIPrCuBr	95	53 (54)	30 (33)
10	SIPrCuI	94	48 (52)	31 (33)
11	[IMes] ₂ CuBF ₄	91	26 (28)	61 (63)
12	[ICy] ₂ PF ₆	94	44 (47)	35 (36)
13	[IPr] ₂ PF ₆	90	37 (41)	47 (48)
14	PyIMesCuCl	96	49 (53)	33 (34)
15	IPr*CuCl	94	71 (78)	7 (8)
16	IPr*CuCl	n.d.	76 ^d	11 ^d

^aReaction conditions: ketone 1a (1.0 mmol), alkyne 2a (1.2 mmol), NHCCuX (0.02 mmol), TMG (0.02 mmol), tetradecane (10 μL), DME (0.1 mL), H₂O (2 mL), 16 h, 100 °C; conversion was based on GC with tetradecane as internal standard. ^bIsolated yield after chromatography. ^cEstimated yield based on GC from calibration curve is given in parentheses (see SI). ^dReaction conducted on 5.0 mmol scale of 1a; n.d., not determined.

Scheme 4. Scope of Alkynes







Figure 3. Representative examples of biologically active steroids bearing heterocyclic substituent.

tolerated under the reaction conditions. 3-Ethynylthiophene furnished product **3g** cleanly in 53% yield, while 3-ethynylpyridine in only 11% yield. Next, we turned our attention to alkyl-substituted alkynes. In those cases, quinolines **3j–p** were formed in good yields in the presence of alkene, ketone, ester, amide or free hydroxyl functional groups. To illustrate the broad scope of substrates for the synthesis of trifluoromethylquinolines further, ferrocene-, β -lactam-, sugar-, and steroid-derived alkynes were selected. Pleasingly, the Friedländer-type reaction furnished the respective heterocycles **3n, q–y** in excellent yield. Only glucose tetraacetate afforded product **3q** in low 28% yield. It should be stressed that the reported yield of quinoline formation in the range of 60–70% is still satisfactory, bearing in mind the competitive self-condensation of *o*-TFMK leading to dibenzo[*b,f*][1,5]diazocine **4a**, observed in all cases.

Finally, the developed methodology was applied for the synthesis of structurally complex and pharmaceutically relevant estrone derivative **3z**, which is of high importance from the perspective of medicinal applications. The class of compounds consisting of a heterocyclic subunit (usually quinolone, isoquinoline or pyridine) attached to the steroid core in position C17 (for numbering, see Scheme 4, structure **3z**) exhibit a broad spectrum of biological activities including antiangiogenic (e.g., natural products of the cortistatin family³²) or proven anticancer ones (e.g., semisynthetic analogue of cardenolides—abiraterone,³³ Figure 3). Recently, Corey has simplified the structure of naturally occurring cortistatins bearing an unusual steroid scaffold to a simple androstane derivative and confirmed its prominent antiangiogenic activity.³⁴ Regarding the synthetic efforts toward cortistatin and its analogues,^{34,35} the key transformation involved a palladium-catalyzed (10–50 mol % of Pd) Stille coupling of a sterically congested steroid vinyl iodide or enol triflate located in a neopentyl position. The application of palladium and tin compounds to the synthesis of biologically active molecules can affect biological evaluation due to toxic heavy metal contamination. The developed method offers an attractive alternative for the construction of heterocycle-steroid hybrids via a palladium-free protocol. The respective estrone derivative **3z** was isolated in 62% yield using only 2 mol % of the IPr*CuCl complex.

Next, we explored variously substituted *o*-TFMKs for the synthesis of quinolines. Ketones bearing strongly and weakly electron-donating groups, such as NMe₂, OMe, Me, F, H as well as a naphthyl moiety furnished the corresponding quinolines **5a,c,d,f–h** and benzo[*h*]quinoline **5b** in moderate to good yields (Scheme 5). Further improvement of the formation of **5a** was accomplished by fine-tuning the electronic properties of NHC ligand. Application of IPr*^{OMe}CuCl complex, introduced by Kobayashi,³⁶ in place of IPr*CuCl resulted in increases in yield, up to 82%. Presumably, this can be attributed to the electron-donating properties of the methoxy group attached to the NHC ligand which enhance

Scheme 5. Scope of Fluoroketones



^a5 mol % of IPr*^{OMe}CuCl was used.


the nucleophilicity of the copper acetylide. Similarly, IPr*^{OMe}CuCl appeared to be the complex of choice for the synthesis of fluorinated 1,6- and 1,8-naphthyridines **5i–k** and **5l**, accessible by other methods only with difficulty.

Further investigations were directed at the synthesis of difluoromethyl-containing quinolines. It is well-established that CF₂H can act as a bioisostere of hydroxyl, *N*-hydroxamic acid and thiol groups,³⁷ which offers new routes for drug design. CF₂H constitutes a good platform for lipophilic interactions as a hydrogen bond donor^{37,38} and may enhance membrane permeability, binding affinity and bioavailability. Although direct introduction of CF₂H onto arenes has become the

subject of intensive research in recent years (including Pd,³⁹ Ni,⁴⁰ Cu⁴¹ or Zn⁴² catalyzed transformations), the developed methods usually need harsh conditions and are incompatible with many functional groups. Furthermore, the complexity of reagent mixtures used or catalytic systems makes these approaches far from practical, especially on a large scale. Bearing in mind the practical aspects, the developed protocol has revealed a simple procedure of difluoromethylquinoline synthesis. Indeed, heating a mixture of difluoromethylketone and a terminal alkyne on water in the presence of 2 mol % IPr^*CuCl and 2 mol % of TMG afforded the respective quinolones **5n–o** in good yields (52–77%), also in the case of cholesterol derivative **5p**. The same conditions appeared compatible with the synthesis of perfluoroalkyl-quinoline **5m**. However, $\text{IPr}^*\text{OMeCuCl}$ had to be used to maintain a reasonable 56% isolated yield.

On the basis of our experiments and literature data,²² a plausible catalytic cycle of the NHCCuX -catalyzed Friedländer reaction leading to quinolines was proposed (Scheme 6). The

Scheme 6. A Plausible Catalytic Cycle^a




^aNHC, N-heterocyclic carbene; TMG, 1,1,3,3-Tetramethylguanidine.

NHCCuX complex interacts with terminal alkyne **A** (via universally accepted π -activation mode) forming the mononuclear copper acetylide **B** and releasing an amine hydrochloride simultaneously (if copper chloride complex is used). The structure of the NHC-copper acetylide was confirmed independently by NMR spectroscopy and X-ray crystallography (by Nolan^{26b} and Jones,²⁵ respectively). Next, the monomeric acetylide **B** undergoes an addition to the fluorinated ketone **D**, affording copper alkoxide **F** which is protonated by the strongest Brønsted acid present in the system—amine hydrochloride. The protonation step regenerates the NHCCuCl complex and the amine needed for the activation of terminal alkyne **A**, closing the catalytic cycle. The spontaneous dehydrative cyclization of the propargyl alcohol **G**, which may be enhanced by the NHCCuX complex via π -activation or by the Brønsted acid,²² affording quinoline **H**. It should be stressed that other side reactions, such as self-condensation or hydration could decrease the yield of quinoline **H**. For those reasons, an equivalent loading of the base and the NHCCuX complex has to be used to prevent the formation of dibenzo[*b,f*][1,5]diazocine **E** (see, Table 1).

The utility of the developed method is further illustrated through a scalable synthesis of a fluorinated analogue **13** of **G** protein-coupled receptor antagonist (known as GPR91, Scheme 7). GPR91 belongs to a class of membrane proteins able to bind an extracellular succinate—an intermediate in the

Scheme 7. Application of the Friedländer-Type Reaction to a Gram-Scale Synthesis of a Fluorinated Analogue of a G Protein-Coupled Receptor Antagonist (GPR91)^a



^aTMG, 1,1,3,3-tetramethylguanidine; HOBt, 1-hydroxybenzotriazole; EDC·HCl, 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride.

Krebs cycle.⁴³ The binding of succinate to GPR91 can affect a wide array of physiological and pathological processes such as inhibition of lipolysis, regulation of blood pressure, cardiac hypertrophy, angiogenesis in retinal tissues, etc.⁴⁴ Among nonpeptide small organic molecules which serve as ligands for GPR91, naphthydrines coupled with biphenyl-derived benzylamine, originally synthesized and evaluated by Merck as inhibitors of Bradykinin B1 receptor⁴⁵ (BK₁R), have witnessed a growing interest.⁴⁶ However, their fluorinated analogues have not been investigated to date. Herein, we present a scalable convergent route to this class of compounds. First, we synthesized fluorinated naphthydrine **5j** applying the developed method on a 0.5 mmol scale which afforded the product in 74% yield. Pleasingly, we found that a 14-fold increase in scale furnished the product cleanly with equally excellent yield, further underlining the practical aspect of the developed method.

The intermediate benzylamine derivative **12** was synthesized by a two-step sequence. The key biphenyl **11** was synthesized via Fe-catalyzed aryl–aryl cross-coupling under conditions developed by Knochel.⁴⁷ Arylcopper reagent **9**, generated from the respective nitrile **8**, was coupled with iodoester **10** to afford biaryl **11** in 81% yield on large scale (1.45 g). It should be noted that homocoupling product was observed when the arylcopper species was generated from iodoester **10**. Subsequent chemoselective reduction of nitrile group to amine appeared to be challenging. BH_3 and common metal hydrides (NaBH_4 in combination with CoCl_2 , CuCl) appeared to be unsuccessful, whereas the reduction in the presence of Raney nickel furnished secondary amine⁴⁸ (for details, see SI). Gratifyingly, Pd-catalyzed reduction in the presence of HCl in MeOH cleanly afforded the respective amine hydrochloride **12** without chromatography on gram scale. The obtained amine

12 was coupled with ester 5j (after hydrolysis of the latter), mediated by the mixture of EDC·HCl/HOBt to give amide 13 with 63% yield after two steps. The evaluation of biological activity of naphthydrine 13 and its analogues are in progress.

CONCLUSION

In summary, we developed an efficient synthesis of trifluoromethylquinolines (and their difluoromethyl- and perfluoroalkyl- analogues) and naphthydrines via tandem direct catalytic alkylation of *o*-aminofluoromethylketones/condensation sequence, for the first time on water in the presence of a catalytic amount of NHC-copper(I) complexes. The established method allows to obtain a series of fluorinated quinolines with good to moderate yields. During the optimization of the reaction conditions, it was found that *o*-aminotrifluoromethylketones undergo base-catalyzed self-condensation leading to a rare example of dibenzo[*b,f*][1,5]diazocine synthesis. Further experiments confirmed that the formation of dibenzo[*b,f*]-[1,5]diazocines is catalyzed by a weak base on water. The studies on the scope of the formation of dibenzo[*b,f*][1,5]-diazocines are underway with promising results.

EXPERIMENTAL SECTION

General Remarks. NMR spectra were recorded in CDCl₃ or DMSO-*d*₆ solutions (unless indicated otherwise); chemical shifts are quoted on the δ scale, ppm, with the solvent signal as the internal standard (CHCl₃, ¹H NMR 7.26 ppm; CDCl₃, ¹³C NMR 77.00 ppm, DMSO-*d*₆ 2.50 ppm, ¹³C NMR 39.40 ppm). High resolution mass spectra (HRMS) were taken using EI technique or electrospray ionization (ESI). Column chromatography was performed on Merck silica gel 60, 230–400 mesh. TLC was performed on aluminum sheets, Merck 60F 254. Anhydrous solvents were obtained by distillation over CaCl₂ (CH₂Cl₂) or Na/benzophenone (THF, hexane, MTBE). Air-sensitive reactions were performed in flame-dried glassware under atmosphere of argon. Organic extracts were dried and solvents were evaporated in a rotary evaporator. Reagents were used as they were purchased unless otherwise indicated (which is specified at beginning of each section). The name of compounds were generated using ACD Lab Name 12.0 software.

Synthesis of N-Heterocyclic Carbene Copper(I) Complexes. [IMes]₂CuPF₆, SIPrAgCl and IPrAuCl were commercially available from Aldrich and used as received. SIMesCuCl,⁴⁹ SIMesCuBr,^{26a} IMesCuCl,⁴⁹ IMesCuBr,⁵⁰ SIPrCuCl,⁴⁹ SIPrCuBr,⁵¹ SIPrCuI,⁵¹ SIPrCuOTf,⁵² SIPrOAc,⁵³ IPrCuCl,⁴⁹ IPrCuBr,⁵¹ IPrCuI,⁵¹ IPr⁺-CuCl,⁴⁹ [ICy]₂CuPF₆^{26b} and [IPr]₂CuPF₆⁵⁴ were prepared followed by literature procedure.

{1,3-bis[2,6-bis(Diphenylmethyl)-4-methoxyphenyl]-1,3-dihydro-2H-imidazol-2-ylidene}chlorocopper. IPr⁺OMeCuCl was prepared applying literature procedure developed by Cazin et al.⁴⁹ In a glovebox, a 20 mL screw-cap vial was charged with K₂CO₃ (281.9 mg, 2.04 mmol, 2.0 equiv), IPr⁺OMeCl (1.0 g, 1.02 mmol), CuCl (100.8 mg, 1.02 mmol, 1.0 equiv) and anhydrous acetone (10 mL). Next the vial was capped, removed from the glovebox and the resulting suspension was vigorously stirred for 20 h at 60 °C (temp. of oil bath). Then solvent was evaporated, DCM (20 mL) was added and the resulting mixture was filtered through a pad of Celite (washing with DCM). The crude copper(I) complex was dissolved in minimum volume of DCM (6 mL) and crashed with *n*-pentane (28 mL). The obtained solid was filtered, washed with *n*-pentane (3 × 10 mL), and dried in vacuo to give IPr⁺OMeCuCl as a white solid (933.3 mg, 88%). ¹H NMR (400 MHz, CD₂Cl₂) δ 7.28–7.18 (m, 24H), 7.13–7.08 (m, 8H), 6.98–6.91 (m, 8H), 6.62 (s, 4H), 5.86 (s, 2H), 5.25 (s, 4H), 3.62 (s, 6H). ¹H NMR data are in agreement with those reported.³⁶

Synthesis of Alkynes. Cyclopropylethyne (2a), ethynylbenzene (2b), 1-ethynyl-4-methoxybenzene (2c), 5-ethynyl-1,2,3-trimethoxybenzene (2d), 1-ethynyl-4-methylbenzene (2e), 3-ethynylpyridine (2f), 3-ethynylthiophene (2g), 1-ethynylcyclohexene (2h), 1-ethynyl-

4-trifluoromethylbenzene (2i), oct-1-yne (2j), 4-methylpent-1-yne (2k), pent-4-yne-1-ol (2l), methyl hex-5-ynoate (2m) and ethynylferrocene (2x) are commercially available and used as received without further purification. 1-(4-Fluorophenyl)pent-4-yn-1-one (2o),²⁴ ethyl hex-5-ynoate (7),⁵⁵ (3 β)-cholest-4-en-3-yl hex-5-ynoate (2r),⁵⁶ 17-ethynyl-3-methoxyestra-1(10),2,4,16-tetraene (2z)⁵⁷ and (3*S*,4*R*)-3-{{(1*R*)-[*tert*-butyl(dimethyl)silyl]oxo}ethyl-4-prop-2-yn-1-yl}azetidine-2-one (2y)⁵⁸ were prepared followed by literature procedure.

Pent-4-yn-1-yl 2,3,4,6-tetra-O-acetyl- α -D-mannopyranoside (2q). To a solution of 1,2,3,4,6-penta-O-acetyl-D-mannopyranose (4.37 g, 11.2 mmol), MS 3 Å (4 g) in anhydrous DCM (80 mL) and 4-pentyn-1-ol (2l) (2.08 mL, 22.4 mmol, 2.0 equiv), cooled to –10 °C, BF₃·Et₂O (11.2 mL, 89.6 mmol, 8.0 equiv) was added dropwise. The resulting mixture was slowly allowed to reach rt and stirred for 16 h. The reaction mixture was then quenched by addition of solid NaHCO₃ (10 g) and stirred at rt. After 30 min the reaction mixture was washed with sat. aqueous NaHCO₃ (3 × 50 mL), dried over MgSO₄, and solvent was evaporated. The residue was chromatographed on silica FCC (15–30% EtOAc/hexanes) to give a light yellow oil (1.55 g, 33%, CAS: 1327252–78–7, no spectral data available for comparison were reported). [a]_D²³ = 46.4 (c = 1.1, CHCl₃); IR (film) 3283, 2958, 2939, 2117, 1751 cm⁻¹; ¹H NMR (400 MHz, CDCl₃) δ 5.32 (dd, *J* = 10.0, 3.2 Hz, 1H), 5.29 (t, *J* = 9.6 Hz, 1H), 5.22 (dd, *J* = 3.2, 1.6 Hz, 1H), 4.80 (d, *J* = 1.6 Hz, 1H), 4.27 (dd, *J* = 12.2, 5.2 Hz, 1H), 4.10 (dd, *J* = 12.3, 2.4 Hz, 1H), 4.00 (ddd, *J* = 9.6, 5.2, 2.4 Hz, 1H), 3.83 (ddd, *J* = 9.6, 7.2, 5.6 Hz, 1H), 3.55 (ddd, *J* = 9.6, 5.6, 5.6 Hz, 1H), 2.35–2.27 (m, 2H), 2.14 (s, 3H), 2.09 (s, 3H), 2.03 (s, 3H), 1.98 (s, 3H), 1.95 (t, *J* = 2.6 Hz, 1H), 1.89–1.73 (m, 2H); ¹³C NMR (100 MHz, CDCl₃) δ 170.6, 170.0, 169.8, 169.7, 97.6, 83.2, 69.6, 69.1, 69.0, 68.5, 66.5, 66.2, 62.4, 27.9, 20.8, 20.7, 20.6, 20.6, 15.2; HRMS (ESI-TOF) *m/z* [M + Na]⁺ Calcd for C₁₉H₂₆O₁₀Na 437.1424, found 437.1416.

Pent-4-yn-1-yl α -D-mannopyranoside (14). To a stirred solution of pent-4-yn-1-yl 2,3,4,6-tetra-O-acetyl- α -D-mannopyranoside (2q) (875.0 mg, 2.24 mmol) in dry MeOH (20 mL), KOMe (15.7 mg, 0.224 mmol, 0.1 equiv) was added at rt and stirred for 3 h. Then solvent was evaporated and residue was passed through pad of silica (10% MeOH/DCM) to give a colorless oil (474.4 mg, 86%). The obtained pent-4-yn-1-yl α -D-mannopyranoside (14) was used without further purification in the next step. [a]_D²³ = –70.7 (c = 1.9, MeOH); ¹³C NMR (100 MHz, CD₃OD) δ 101.6, 84.3, 74.5, 72.7, 72.2, 69.9, 68.5, 66.9, 62.8, 29.6, 15.9; HRMS (ESI-TOF) *m/z* [M + Na]⁺ Calcd for C₁₁H₁₈O₆Na 269.1001, found 269.0991.

(3*aS*,4*S*,5*aR*,9*aR*,9*bS*)-2,2,8,8-Tetramethyl-4-(pent-4-yn-1-yloxy)-hexahydro[1,3]dioxolo[4,5]pyrano [3,2-*d*][1,3]dioxine (2n). To a stirred rt solution of the tetraol 14 (0.397 g, 1.71 mmol) in dry DMF (13 mL) under atmosphere of argon, Me₂C(OMe)₂ (1.32 mL, 10.9 mmol, 10.0 equiv) and *p*-TsOH (20.9 mg, 0.11 mmol, 0.1 equiv) were added at rt. The reaction mixture was stirred for 3 h before acetone (2.7 mL) was introduced. After 24 h the reaction was diluted with Et₂O (20 mL) and washed with sat. NaHCO₃ solution (2 × 20 mL). The organic layer was separated, washed with H₂O (3 × 20 mL), brine (2 × 30 mL), dried over Na₂SO₄, filtered and concentrated in vacuo. The residue was purified by chromatography on silica (5% EtOAc/hexanes) to give diacetal 2n as a colorless oil (441.0 mg, 79%). α = –70.7 (c = 1.9, MeOH); IR (film) 3278, 2990, 2939, 2915, 2876, 2117 cm⁻¹; ¹H NMR (400 MHz, CDCl₃) δ 5.00 (s, 1H), 4.18–4.09 (m, 2H), 3.87 (dd, *J* = 10.8, 5.6 Hz, 1H), 3.84–3.69 (m, 3H), 3.63–3.44 (m, 2H), 2.30 (dt, *J* = 7.2, 2.8 Hz, 2H), 1.95 (t, *J* = 2.8 Hz, 1H), 1.86–1.74 (m, 2H), 1.54 (s, 3H), 1.51 (s, 3H), 1.42 (s, 3H), 1.34 (s, 3H); ¹³C NMR (100 MHz, CDCl₃) δ 109.4, 99.7, 97.8, 83.3, 76.1, 74.9, 72.7, 68.8, 65.9, 62.1, 61.4, 29.0, 28.2, 28.1, 26.1, 18.8, 15.2; HRMS (ESI-TOF) *m/z* [M + Na]⁺ Calcd for C₁₇H₂₆O₆Na 349.1627, found 349.1629.

***N*-[(1*S*)-1-Phenylethyl]hex-5-ynamide (2p).** To a solution of 5-hexynoic acid (1 g, 8.91 mmol) in DCM (20 mL), cooled to 0 °C, EDC (2.05 g, 10.7 mmol, 1.2 equiv) and (*S*)-methylbenzylamine (1 g, 8.91 mmol, 1.2 equiv) were added, and stirred for 3 h at rt. Then reaction mixture was diluted with water (40 mL) and organic phase was separated, washed with 5% HCl_{aq} (2 × 20 mL), dried over MgSO₄

and evaporated. The residue was passed through a pad of silica (eluted with 40% EtOAc/hexanes) to give a waxy solid (1.83 g, 95%). $[\alpha]_D^{25} = -92.7$ ($c = 0.94$, CHCl_3); IR (film) 3292, 3063, 2972, 2934, 2116, 1614, 1545 cm^{-1} ; $^1\text{H NMR}$ (400 MHz, CDCl_3) δ 7.37–7.23 (m, 5H), 5.83 (br s, $J = 6.3$ Hz, 1H), 5.19–5.06 (m, 1H), 2.37–2.19 (m, 4H), 1.96 (t, $J = 2.6$ Hz, 1H), 1.91–1.80 (m, 2H), 1.48 (d, $J = 6.9$ Hz, 3H); $^{13}\text{C NMR}$ (100 MHz, CDCl_3) δ 171.2, 143.2, 128.6, 127.3, 126.1, 83.5, 69.2, 48.7, 35.1, 24.1, 21.7, 17.8; HRMS (ESI-TOF) m/z $[\text{M} + \text{Na}]^+$ Calcd for $\text{C}_{14}\text{H}_{17}\text{NONa}$ 238.1208, found 238.1204.

Synthesis of *ortho*-Aminotrifluoromethylketones (*o*-TFMK's) and Their Derivatives Containing Difluoromethyl Group and Perfluoroalkyl Chain. 1-(2-Amino-5-chlorophenyl)-2,2,2-trifluoroethanone (**1a**),^{6a} 2,2-difluoro-1-(morpholin-4-yl)ethanone⁵⁹ were prepared according to literature procedure. 1-(2-Amino-5-chloropyridin-3-yl)-2,2-difluoroethanone is commercially available and was used as received.

General Procedure. To a solution of amide (x mmol) and TMEDA (1.0 equiv), cooled to -20 °C (or lower temp.) in MTBE (or THF), a solution of *n*-BuLi (2.2 equiv) was added dropwise by means of syringe pump within 30 min to 2 h while the temperature was kept below -10 °C (or lower as indicated). The mixture was aged at -5 – 5 °C for 2–4 h, cooled below -30 °C (or -65°) and $\text{CF}_3\text{CO}_2\text{Et}$ (1.4 equiv) or other source of fluorinated group was added. Then reaction mixture was stirred for 0.5–1 h at rt, quenched with 5% HCl (or 10% citric acid). Then solvents were evaporated. In some cases product was separated by chromatography or crystallization from unreacted substrate. Then residue was treated with 36% aqueous HCl or its solution in dioxane (4 M in dioxane), and stirred for 2–16 h at 70 – 90 °C (temp. of oil bath). Then reaction mixture was neutralized with sat. solution of K_2CO_3 (or NaHCO_3) and extracted with EtOAc. The combined organic extracts were washed with brine, dried over MgSO_4 and evaporated. The residue was chromatographed on silica and further purified by crystallization (usually from *n*-heptane) to give a pure *ortho*-aminofluorophenones and its derivatives.

1-(2-Amino-5-methoxyphenyl)-2,2,2-trifluoroethanone (1b). To a solution of amide *N*-(4-methoxyphenyl)-2,2-dimethylpropanamide (11.41 g, 55.1 mmol) in Et_2O (60 mL) and TMEDA (8.5 mL, 55.1 mmol, 1.0 equiv), cooled to -20 °C, a solution of *n*-BuLi (48.5 mL, 121.2 mmol, 2.2 equiv, *n*-BuLi 2.5 M in hexanes) was added dropwise while the temperature was kept below 0 °C. The mixture was aged at 0 – 5 °C for 4 h and cooled below -20 °C, and $\text{CF}_3\text{CO}_2\text{Et}$ (8.0 mL, 67.2 mmol, 1.4 equiv) was added rapidly (internal temp. reached 10 °C). Then reaction mixture was stirred for 1 h at rt, quenched with 5% HCl (40 mL). The aqueous phase was separated and extracted with MTBE (3×50 mL). The residue was treated with 36% HCl (20 mL), and stirred for 16 h at 90 °C (temp. of oil bath). Then reaction mixture was cooled to 0 °C and washed with EtOAc to give a white solid. The obtained solid was suspended in MTBE (40 mL) and treated with aq sat. solution of NaOAc (80 mL). After 30 min of vigorous stirring, organic phase was separated, dried over MgSO_4 , and evaporated. The residue was chromatographed on silica (5–15% EtOAc/hexanes) to give an orange solid (1.64 g, 14%). $^1\text{H NMR}$ (400 MHz, CDCl_3) δ 7.18–7.13 (m, 1H), 7.09 (dd, $J = 9.1$, 2.8 Hz, 1H), 6.69 (d, $J = 9.1$ Hz, 1H), 6.23 (br s, 2H), 3.78 (s, 3H); $^{13}\text{C NMR}$ (100 MHz, CDCl_3) δ 180.1 (q, $J_{\text{CF}} = 33.0$ Hz), 150.0, 148.7, 127.4, 118.9, 117.1 (q, $J_{\text{CF}} = 289.8$ Hz), 111.4 (q, $J_{\text{CF}} = 4.3$ Hz), 110.4, 55.8; $^{19}\text{F NMR}$ (376 MHz, CDCl_3) δ -69.9 . $^1\text{H NMR}$ data are in agreement with those reported.⁶⁰ $^{13}\text{C NMR}$ spectra is described by authors without C–F coupling constants and the accurate description and the copy of spectra are included in this Experimental Section.

1-(1-Aminonaphthalene-2-yl)-2,2,2-trifluoroethanone (1c). To a solution of 2,2-dimethyl-*N*-(naphthalen-1-yl)propanamide (10.0 g, 44.0 mmol) in MTBE (80 mL) and TMEDA (6.8 mL, 44.0 mmol, 1.0 equiv), cooled to -20 °C, a solution of *n*-BuLi (38.7 mL, 96.8 mmol, 2.2 equiv, BuLi 2.5 M in hexane) was added dropwise by means of syringe pump within 2 h while the temperature was kept below -10 °C. The mixture was aged at -5 – 0 °C for 2 h and cooled below -30 °C, and $\text{CF}_3\text{CO}_2\text{Et}$ (7.35 mL, 61.8 mmol, 1.4 equiv) was added rapidly (internal temp. reached 20 °C). Then reaction mixture was stirred for 1 h at rt, quenched with 5% HCl (40 mL) and solvents were

evaporated. The residue was treated with 36% HCl (20 mL), and stirred for 5 h at 70 °C (temp. of oil bath). Then reaction mixture was neutralized with sat. solution of K_2CO_3 and extracted with EtOAc (4×30 mL). The combined organic extracts were washed with brine (1×30 mL), dried over MgSO_4 , and evaporated. The residue was chromatographed on silica (toluene) and further purified by crystallization (*n*-heptane) to give a bright-yellow solid (3.03 g, 29%). mp 137.5 – 138.6 °C (*n*-heptane); IR (KBr) 3461, 3313, 1647, 1614 cm^{-1} ; $^1\text{H NMR}$ (400 MHz, CDCl_3) δ 8.01–7.70 (br s, 2H) overlapping 7.94–7.90 (pseudo dd, 1H) and 7.75–7.71 (m, 1H), 7.69–7.71 (m, 2H), 7.55–7.48 (m, 1H), 7.05 (d, $J = 9.1$ Hz, 1H); $^{13}\text{C NMR}$ (100 MHz, CDCl_3) δ 179.9 ($J_{\text{CF}} = 32.9$ Hz), 153.3, 136.8, 130.6, 128.7, 126.1, 125.1 ($J_{\text{CF}} = 4.3$ Hz), 122.6, 121.9, 117.5 ($J_{\text{CF}} = 289.4$ Hz), 116.4, 105.3; $^{19}\text{F NMR}$ (376 MHz, CDCl_3) δ -69.2 ; HRMS (ESI-TOF) m/z $[\text{M} + \text{H}]^+$ Calcd for $\text{C}_{12}\text{H}_9\text{F}_3\text{NO}$ 240.0636, found 240.0632.

1-(2-Amino-5-fluorophenyl)-2,2,2-trifluoroethanone (1d). To a solution of *N*-(4-fluorophenyl)-2,2-dimethylpropanamide (9.37 g, 48.0 mmol) in MTBE (150 mL) and TMEDA (7.4 mL, 48.0 mmol, 1.0 equiv), cooled to -20 °C, a solution of *n*-BuLi (45.8 mL, 109.0 mmol, 2.27 equiv, BuLi 2.38 M in hexanes) was added dropwise while the temperature was kept below 0 °C. The mixture was aged at 0 – 5 °C for 2 h and cooled below -20 °C, and $\text{CF}_3\text{CO}_2\text{Et}$ (8.0 mL, 67.2 mmol, 1.4 equiv) was added rapidly (internal temp. reached 10 °C). Then reaction mixture was stirred for 1 h at rt, quenched with 5% HCl (40 mL) and solvents were evaporated. The residue was treated with 36% HCl (20 mL), and stirred for 3 h at 70 °C (temp. of oil bath). Then reaction mixture was cooled to 0 °C and washed with EtOAc to give a white solid. The obtained solid was suspended in MTBE (40 mL) and treated with aq sat. solution of NaOAc (80 mL). After 30 min of vigorous stirring, organic phase was separated, dried over MgSO_4 , and evaporated. The residue was crystallized from *n*-heptane to give a bright-yellow solid (7.65 g, 77%). $^1\text{H NMR}$ (400 MHz, CDCl_3) δ 7.45–7.39 (m, 1H), 7.21–7.14 (m, 1H), 6.70 (dd, $J = 9.2$, 4.5 Hz, 1H), 6.36 (br s, 2H, NH); $^{13}\text{C NMR}$ (100 MHz, CDCl_3) δ 180.7 (dq, $J_{\text{CF}} = 34.0$, 3.3 Hz, C=O), 153.2 (d, $J_{\text{CF}} = 238.4$ Hz), 150.0, 125.7 (d, $J_{\text{CF}} = 24.3$ Hz), 118.9 (d, $J_{\text{CF}} = 7.1$ Hz), 116.8 (q, $J_{\text{CF}} = 289.5$ Hz), 115.3 (dq, $J_{\text{CF}} = 23.4$, 4.3 Hz), 110.0 (d, $J_{\text{CF}} = 6.6$ Hz); $^{19}\text{F NMR}$ (376 MHz, CDCl_3) δ -70.1 , -127.1 . CAS registry number 214288–07–0, no spectroscopic data are available for comparison.

1-(2-Aminophenyl)-2,2,2-trifluoroethanone (1e). To a solution of 2,2-dimethyl-*N*-phenylpropanamide (7.80 g, 44.0 mmol) in MTBE (100 mL) and TMEDA (6.8 mL, 44.0 mmol, 1.0 equiv), cooled to -20 °C, a solution of *n*-BuLi (38.7 mL, 96.8 mmol, 2.2 equiv, *n*-BuLi 2.5 M in hexane) was added dropwise by means of syringe pump within 2 h while the temperature was kept below -10 °C. The mixture was aged at 25 °C for 3 h (yellow solid has formed), cooled below -25 °C, and $\text{CF}_3\text{CO}_2\text{Et}$ (7.35 mL, 61.8 mmol, 1.4 equiv) was added rapidly (internal temp. reached 0 °C). Then reaction mixture was stirred for 16 h at rt and quenched with 5% HCl (100 mL). The organic phase was separated and solvents were evaporated. The residue was chromatographed on silica (5–10% EtOAc/hexanes) to give a yellow oil (5.1 g) and unreacted substrate (1.6 g). The crude TFMK was treated with 36% HCl (20 mL) at rt (white solid was formed immediately) and stirred for 3 h at 90 °C (temp. of oil bath, yellow solution has been formed at 70 °C). Then reaction mixture was neutralized with sat. solution of Na_2CO_3 and extracted with EtOAc (4×30 mL). The combined organic extracts were washed with brine (1×30 mL), dried over MgSO_4 , and evaporated. The residue was purified by crystallization (*n*-heptane, 8 mL, -40 °C, 2 h) to give a bright yellow solid (2.66 g, 32%). $^1\text{H NMR}$ (400 MHz, CDCl_3) δ 7.82–7.73 (m, 1H), 7.43–7.36 (m, 1H), 6.77–6.68 (m, 2H), 6.45 (br s, 2H, NH); $^{13}\text{C NMR}$ (100 MHz, CDCl_3) δ 180.8 (q, $J_{\text{CF}} = 33.1$ Hz), 151.1, 136.6, 131.3 (q, $J_{\text{CF}} = 4.1$ Hz), 117.4, 117.1 (q, $J_{\text{CF}} = 289.7$ Hz), 116.4, 111.2; $^{19}\text{F NMR}$ (376 MHz, CDCl_3) δ -69.6 . $^1\text{H NMR}$ data are in agreement with those reported.⁶⁰ $^{13}\text{C NMR}$ spectra is described by authors without C–F coupling constants and the accurate description and the copy of spectra are included in this Experimental Section.

1-[2-Amino-5-(trifluoromethyl)phenyl]-2,2,2-trifluoroethanone (1f). To a solution of 2,2-dimethyl-*N*-[4-(trifluoromethyl)phenyl]-

propanamide (10.8 g, 44.0 mmol) in MTBE (130 mL) and TMEDA (6.8 mL, 44.0 mmol, 1.0 equiv), cooled to $-20\text{ }^{\circ}\text{C}$, a solution of *n*-BuLi (38.7 mL, 96.8 mmol, 2.2 equiv, *n*-BuLi 2.5 M in hexane) was added dropwise by means of syringe pump within 1 h while the temperature was kept below $-20\text{ }^{\circ}\text{C}$. The mixture was aged at $0\text{--}5\text{ }^{\circ}\text{C}$ for 2 h (a brown-black solid has been formed), cooled below $-25\text{ }^{\circ}\text{C}$, and $\text{CF}_3\text{CO}_2\text{Et}$ (7.35 mL, 61.8 mmol, 1.4 equiv) was added rapidly (internal temp. reached $0\text{ }^{\circ}\text{C}$). Then reaction mixture was stirred for 1 h at rt, quenched with 5% HCl (100 mL) and organic phase was separated and solvents were evaporated. The yellow-green residue was treated with 36% HCl (100 mL), and stirred for 16 h at $90\text{ }^{\circ}\text{C}$ (temp. of oil bath). Then reaction mixture was neutralized with solid Na_2CO_3 and extracted with EtOAc ($4 \times 30\text{ mL}$). The combined organic extracts were washed with brine ($1 \times 30\text{ mL}$), dried over MgSO_4 , and evaporated. The residue was chromatographed on silica (10% EtOAc/hexanes) to give a bright yellow solid (4.44 g, pure fraction). Additional 1.89 g of product was obtained by crystallization (*n*-heptane) of mixed fraction after chromatography. (4.44 g + 1.89 g, 56%). $^1\text{H NMR}$ (400 MHz, CDCl_3) δ 8.05 (s, 1H), 7.58 (dd, $J = 8.9, 1.8\text{ Hz}$, 1H), 6.83 (d, $J = 2.2\text{ Hz}$, 1H), 6.75 (br s, NH, 2H); $^{13}\text{C NMR}$ (100 MHz, CDCl_3) δ 180.7 (q, $J_{\text{CF}} = 34.0\text{ Hz}$), 154.7, 132.6 (q, $J_{\text{CF}} = 3.0\text{ Hz}$), 129.3–129.0 (m), 123.8 (q, $J_{\text{CF}} = 269.3\text{ Hz}$), 118.6 (q, $J_{\text{CF}} = 33.4\text{ Hz}$), 118.1, 116.7 (q, $J_{\text{CF}} = 289.4\text{ Hz}$), 109.9; $^{19}\text{F NMR}$ (376 MHz, CDCl_3) δ $-62.3, -69.8$. $^1\text{H NMR}$ data are in agreement with those reported.⁶⁰ $^{13}\text{C NMR}$ spectra is described by authors without C–F coupling constants and the accurate description and the copy of spectra are included in this [Experimental Section](#).

1-[2-Amino-5-(dimethylamino)phenyl]-2,2,2-trifluoroethanone (1g). To a solution of *N*-[4-(dimethylamino)phenyl]-2,2-dimethylpropanamide (4.99 g, 22.66 mmol) and TMEDA (45.34 mmol, 6.95 mL, 2.0 equiv) in THF, cooled to $-60\text{ }^{\circ}\text{C}$, *n*-BuLi (19.9 mL, 45.34 mmol, 2.2 equiv, 2.28 M in hexane) was added dropwise by means of syringe pump within 30 min. (temp. has increased to $-50\text{ }^{\circ}\text{C}$), and the reaction was stirred for 4 h at $0\text{ to }-5\text{ }^{\circ}\text{C}$ degree (internal temperature; reaction mixture was stirred by means of mechanical stirrer due to lithium dianion precipitation). Then reaction mixture was cooled to $-65\text{ }^{\circ}\text{C}$ and $\text{CF}_3\text{CO}_2\text{Et}$ (3.77 mL, 31.73 mmol, 1.4 equiv) was added within 5 min (the internal temp. has risen to $-35\text{ }^{\circ}\text{C}$). Then cooling bath was removed, and the reaction mixture was allowed to warm up to $0\text{ }^{\circ}\text{C}$ and stirred for additional 1 h at this temp. and quenched with 10% citric acid (100 mL). Then mixture was diluted with EtOAc (100 mL), and aqueous phase was extracted with EtOAc ($2 \times 50\text{ mL}$). The combined organic phases were washed with brine ($2 \times 100\text{ mL}$), dried over MgSO_4 , evaporated and dried in vacuo to give an orange foam. The residue was chromatographed on silica (20% EtOAc/hexanes) to give a brown oil contains some impurities. Protected aminofluoroketone was used in the next step without further purification.

The crude aminofluoroketone derivative was treated with HCl in dioxane (20 mL, 4 M in dioxane) and water (2 mL) and resulting mixture was heated at $90\text{ }^{\circ}\text{C}$ for 16 h. Then reaction mixture was neutralized with sat. solution of Na_2CO_3 (100 mL), and aqueous phase was extracted with EtOAc ($3 \times 50\text{ mL}$). The combined organic phases were washed with brine ($2 \times 100\text{ mL}$), dried over MgSO_4 , and evaporated. The residue purified by chromatography (25% EtOAc/hexanes) to give a brown-black oil which solidified upon solid in the fridge (720.2 mg, 14%). mp $72.2\text{--}73.0\text{ }^{\circ}\text{C}$ (*n*-heptane); $^1\text{H NMR}$ (400 MHz, CDCl_3) δ 7.13 (dd, $J = 8.9, 2.8\text{ Hz}$, 1H), 7.08–7.03 (m, 1H), 6.69 (d, $J = 9.1\text{ Hz}$, 1H), 6.08 (br s, NH, 2H), 2.84 (s, CH_3 , 6H); $^{13}\text{C NMR}$ (100 MHz, CDCl_3) δ 180.4 (q, $J_{\text{CF}} = 32.7\text{ Hz}$), 146.9, 142.3, 127.2, 118.5, 117.2 (q, $J_{\text{CF}} = 289.9\text{ Hz}$), 113.3 (q, $J_{\text{CF}} = 4.3\text{ Hz}$), 111.3, 41.9; $^{19}\text{F NMR}$ (376 MHz, CDCl_3) δ -69.8 . The structure of ketone **1g** has reported by Patel,⁶¹ however no spectroscopic data are available for comparison (no CAS registry number). Copy of spectra are included in this [Experimental Section](#).

1-(2-Amino-5-methylphenyl)-2,2,2-trifluoroethanone (1h). To a solution of 2,2-dimethyl-*N*-(4-methylphenyl)propanamide (8.42 g, 44.0 mmol) in MTBE (100 mL) and TMEDA (6.8 mL, 44.0 mmol, 1.0 equiv), cooled to $-20\text{ }^{\circ}\text{C}$, a solution of *n*-BuLi (38.7 mL, 96.8 mmol, 2.2 equiv, *n*-BuLi 2.5 M in hexane) was added dropwise by

means of syringe pump within 1 h while the temperature was kept below $-10\text{ }^{\circ}\text{C}$. The mixture was aged at $10\text{--}15\text{ }^{\circ}\text{C}$ for 5 h (a light-yellow solid has been formed), cooled below $-25\text{ }^{\circ}\text{C}$, and $\text{CF}_3\text{CO}_2\text{Et}$ (7.35 mL, 61.8 mmol, 1.4 equiv) was added rapidly (internal temp. reached $0\text{ }^{\circ}\text{C}$). Then reaction mixture was stirred for 16 h at rt and quenched with 5% HCl (100 mL). The organic phase was separated and the aqueous phase was extracted with EtOAc ($3 \times 20\text{ mL}$). Then combined organic phases were washed with brine ($1 \times 100\text{ mL}$), dried over MgSO_4 and evaporated. The residue was chromatographed on silica (5% EtOAc/hexanes) to give a yellow oil (8.31 g) and unreacted substrate (**S45**). The crude TFMK was treated with 36% HCl (30 mL) at rt (white solid was formed immediately) and stirred for 16 h at $90\text{ }^{\circ}\text{C}$ (temp. of oil bath, gray solid has been formed). Then reaction mixture was cooled to rt, neutralized with sat. solution of Na_2CO_3 (pH = 9) and extracted with EtOAc ($4 \times 30\text{ mL}$). The combined organic extracts were washed with brine ($1 \times 30\text{ mL}$), dried over MgSO_4 , and evaporated. The residue was purified by crystallization (*n*-heptane, 12 mL , $-45\text{ }^{\circ}\text{C}$, 2 h) to give an orange solid (4.59 g, 51%). $^1\text{H NMR}$ (400 MHz, CDCl_3) δ 7.51 (br s, 1H), 7.21 (dd, $J = 8.6, 2.0\text{ Hz}$, 1H), 6.65 (d, $J = 8.6\text{ Hz}$, 1H), 6.30 (br s, 2H), 2.26 (s, 3H, CH_3); $^{13}\text{C NMR}$ (100 MHz, CDCl_3) δ 180.6 (q, $J_{\text{CF}} = 33.1\text{ Hz}$), 151.3, 138.2, 130.3 (q, $J_{\text{CF}} = 4.0\text{ Hz}$), 125.4, 117.5, 117.1 (q, $J_{\text{CF}} = 289.8\text{ Hz}$), 111.0, 20.4; $^{19}\text{F NMR}$ (376 MHz, CDCl_3) δ -69.5 . CAS registry number 205756–35–0; no spectroscopic data are available for comparison. Copy of spectra are included in this [Experimental Section](#).

(1*R*,2*S*,5*R*)-5-Methyl-2-(propan-2-yl)cyclohexyl 4-nitrophenyl ether (15). Title compound was prepared by literature procedure,⁶² however 75% isolated reported in the literature has not been achieved. To a solution of *p*-chloronitrobenzene (11.03 g, 70 mmol) and (–)-mentol (10.93 g, 70 mmol) in dry DMSO (120 mL), a suspension of NaH (3.1 g, 77.0 mmol, 1.1 equiv) was added in portions at rt (evolution of hydrogen has not been observed). The reaction mixture was heated at $70\text{--}75\text{ }^{\circ}\text{C}$ (bath temp.; *strong evolution of hydrogen!*) and the reaction mixture was kept at this temp. for 16 h. Then reaction mixture cooled to rt, diluted with 5% HCl (300 mL) and extracted with EtOAc ($3 \times 100\text{ mL}$). The combined organic extracts were washed with brine ($3 \times 100\text{ mL}$), dried over MgSO_4 and evaporated. The obtained black oil was adsorbed on silica (50 g) and was washed with a mixture of EtOAc and hexanes (5% EtOAc/hexanes) to give an orange oil which was further purified by crystallization from MeOH (70 mL) to give an light-orange solid (6.21 g, 32%). CAS registry number 85002–82–0, 94730–54–8, no spectroscopic data are available for comparison. IR (KBr) 3298, 2956, 2921, 2871, 1647, 1510 cm^{-1} ; $^1\text{H NMR}$ (400 MHz, CDCl_3) δ 8.21–8.14 (m, 2H, = C–H), 6.96–6.90 (m, 2H, = C–H), 4.16 (ddd, $J = 10.6, 10.6, 4.2\text{ Hz}$, 1H, CHOAr), 2.16–2.05 (m, 2H), 1.79–1.70 (m, 2H), 1.61–1.45 (m, 2H), 1.18–0.96 (m, 3H), 0.94 (d, $J = 7.7\text{ Hz}$, 3H), 0.92 (d, $J = 8.1\text{ Hz}$, 3H), 0.75 (d, $J = 7.0\text{ Hz}$, 3H); $^{13}\text{C NMR}$ (100 MHz, CDCl_3) δ 163.70, 141.0, 126.0, 115.00, 78.4, 47.8, 39.9, 34.3, 31.4, 26.3, 23.8, 22.0, 20.6, 16.6.

4-[[[(1*R*,2*S*,5*R*)-5-Methyl-2-(propan-2-yl)cyclohexyl]oxy]anyl]aniline (16). To a solution of nitrocompound **15** (6.21 g, 22.4 mmol) in reagent-grade EtOAc (100 mL), 10% Pd/C (238.3 mg, 0.22 mmol, 1 mol %) was added and the resulting mixture was shaken in Parr apparatus for 4 h at rt (H_2 pressure -4 bar ; in some cases reduction of nitro group has appeared strongly exothermic and the respective caution should be maintained; temp. of the reaction mixture has increased from $17\text{ to }24\text{ }^{\circ}\text{C}$ within 30 min). Then argon was bubbled through the reaction mixture for 5 min and palladium catalyst was filtered through a pad of Celite (washed with EtOAc), and solvent was evaporated to give a light-yellow oil (5.5 g). The crude amine **S35** product was used in the next step without further purification. CAS registry number 94730–56–0, 94661–07–1.

2,2-Dimethyl-*N*-(4-[[[(1*R*,2*S*,5*R*)-5-methyl-2-(propan-2-yl)cyclohexyl]oxy]phenyl]propanamide (17). To a solution of aniline **16** (5.50 g, 22.4 mmol) and Et_3N (4.7 mL, 33.6 mmol) in DCM, cooled to $0\text{ }^{\circ}\text{C}$, PivCl (3.5 mL, 29.1 mmol, 1.3 equiv) was added dropwise. After 10 min cooling bath was removed and reaction mixture was stirred for 16 h at rt. Then reaction mixture was diluted with 5% HCl (100 mL), organic phase was separated, dried over MgSO_4 , and evaporated. The residue was purified by crystallization (*n*-heptane, 90

mL) to give a white crystalline amide **17** (6.68 g, 90%). mp 168.6–169.2 °C (*n*-heptane); $[\alpha]_D^{25} = -45.3$ ($c = 1.0$, CHCl_3); $^1\text{H NMR}$ (400 MHz, CDCl_3) δ 7.41–7.35 (m, 2H), 7.21 (br, 1H, NH) 6.88–6.82 (m, 2H), 3.95 (ddd, $J = 10.6, 10.6, 4.1$ Hz, 1H, CHO), 2.35–2.16 (m, 1H), 2.15–2.07 (m, 1H), 1.76–1.65 (m, 2H), 1.54–1.36 (m, 2H), 1.30 [s, 9H, $\text{NHC}(\text{CH}_3)_3$], 1.17–0.86 (m, 4H) overlapping 0.92 (d, $J = 7.0$ Hz, 3H) and 0.91 (d, $J = 6.5$ Hz, 3H), 0.76 (d, $J = 7.0$ Hz, 2H); $^{13}\text{C NMR}$ (100 MHz, CDCl_3) δ 176.3 (C=O), 163.7, 141.0, 126.0, 115.0, 78.4, 47.8, 39.9, 34.3, 31.4, 26.4, 23.8, 22.0, 20.6, 16.6; HRMS (ESI-TOF) m/z $[\text{M} + \text{Na}]^+$ Calcd for $\text{C}_{21}\text{H}_{33}\text{NO}_2\text{Na}$ 354.2409, found 354.2409.

2,2-Dimethyl-N-[4-[[[(1*R*,2*S*,5*R*)-5-methyl-2-(propan-2-yl)cyclohexyl]oxy]-2-(trifluoroacetyl)phenyl]propanamide (18). To a solution of amide **17** (6.50 g, 19.6 mmol) and TMEDA (3.02 mL, 19.6 mmol, 1.0 equiv) in anhydrous MTBE (50 mL), cooled to -20 °C, *n*-BuLi (18.7 mL, 43.1 mmol, 2.2 equiv, *n*-BuLi 2.31 M in hexane) was added dropwise by means of syringe pump within 40 min. (the internal temp. has increased to -8 °C). Then cooling bath was removed and the resulting reaction mixture was stirred for 4 h at 20 °C (bright-yellow precipitate has formed). Then reaction mixture was cooled to -25 °C, and $\text{CF}_3\text{CO}_2\text{Et}$ (3.3 mL, 27.4 mmol, 1.4 equiv) was added rapidly (internal temp. has increased to 10 °C) and reaction mixture was stirred at rt for 1.5 h. The resulting reaction mixture was quenched with 5% HCl (200 mL), and aqueous phase was extracted with EtOAc (3×50 mL). The combined organic extracts were washed with brine (2×100 mL), dried over MgSO_4 , and evaporated. The residue was chromatographed on silica (5% EtOAc/hexanes) to give a bright orange oil (4.68 g, 56%). The resulting amide **18** was used in the next step without further purification.

1-(2-Amino-5-[[[(1*R*,2*S*,5*R*)-5-methyl-2-(propan-2-yl)cyclohexyl]oxy]phenyl]-2,2,2-trifluoroethanone (1i). To round-bottom flask containing amide **18** (4.2 g, 9.82 mmol), HCl in dioxane (35 mL, 4 M in dioxane) and water (5 mL) were added and stirred for 2 h at 90 °C (TLC analysis indicated absence of substrate, 5% EtOAc/hexanes). Then reaction mixture was cooled to rt, diluted with DCM (50 mL), neutralized with solid NaHCO_3 (ca. 12 g) and stirred for additional 15 min. Then solid was filtered, washed with DCM (5 times), and solvents were evaporated. The residue was chromatographed on silica (5% EtOAc/hexanes) to give an deep-orange oil (2.98 g, 88%). $\alpha = -113.6$ ($c = 0.69$, CHCl_3); IR (film) 3483, 3367, 2957, 2927, 2871, 1668, 1592, 1547, 1489 cm^{-1} ; $^1\text{H NMR}$ (400 MHz, CDCl_3) δ 7.25–7.21 (m, 1H), 7.09 (dd, $J = 9.1, 2.8$ Hz, 1H), 6.67 (d, $J = 9.1$ Hz, 1H), 6.19 (br s, 2H), 3.08 (ddd, $J = 10.5, 10.5, 4.2$ Hz, 1H), 2.32–2.20 (m, 1H), 2.12–2.02 (m, 1H), 1.76–1.63 (m, 2H), 1.52–1.34 (m, 2H), 1.14–0.86 (m, 3H) overlapping 0.94 (d, $J = 6.8$ Hz, 3H) and 0.91 (d, $J = 7.0$ Hz, 3H), 0.81 (d, $J = 7.0$ Hz, 3H); $^{13}\text{C NMR}$ (100 MHz, CDCl_3) δ 180.2 (q, $J_{\text{CF}} = 33.0$ Hz), 148.6, 148.5, 129.4, 118.7, 117.1 (q, $J_{\text{CF}} = 289.8$ Hz), 116.5 (q, $J_{\text{CF}} = 4.2$ Hz), 110.8, 79.8, 48.1, 40.4, 34.5, 31.4, 25.9, 23.5, 22.1, 20.8, 16.3; $^{19}\text{F NMR}$ (376 MHz, CDCl_3) δ -69.8 ; HRMS (ESI-TOF) m/z $[\text{M} + \text{H}]^+$ Calcd for $\text{C}_{18}\text{H}_{25}\text{F}_3\text{NO}_2$ 344.1837, found 344.1830.

1-(2-Amino-5-chlorophenyl)-2,2,3,3,4,4,4-heptafluorobutan-1-on (1j). To a solution of *N*-(4-chlorophenyl)-2,2-dimethylpropanamide (5 g, 23.62 mmol) and TMEDA (23.62 mmol, 3.6 mL) in anhydrous THF (50 mL), cooled to -20 °C, *n*-BuLi (22.8 mL, 51.96 mmol, 2.2 equiv, 2.28 M) was added dropwise by means of syringe pump within 30 min (the internal temp. has increased to -8 °C; a white precipitated which was formed has been dissolved to give an orange solution). The resulting reaction mixture was stirred for 4 h at 0 °C (bright-yellow precipitate has formed). Then reaction mixture was cooled to -30 °C, and ethyl heptafluorobutanoate (5.7 mL, 33.1 mmol, 1.4 equiv) was added rapidly (internal temp. has increased to 10 °C), cooling bath was removed, stirring was continued for 1 h and the reaction mixture was quenched with water (100 mL). The aqueous phase was separated and extracted with EtOAc (3×30 mL). The combined organic extracts were washed with brine (2×30 mL), dried over MgSO_4 , and evaporated. The residue was chromatographed on silica (200 g, 10% EtOAc/hexanes) to give a yellow oil (2.11 g) which was used in the next step without further purification.

The obtained partially purified ketone was treated with solution of HCl in dioxane (10 mL, 4M) and water (1 mL), and reaction mixture was heated at 90 °C for 2 h (TLC indicated absence of substrate). Then solvent was evaporated and crude amine hydrochloride (*attempts to separate of free aminoketone from byproducts have failed*) was purified by chromatography on silica (5–25% EtOAc/hexanes) to give a bright-yellow oil. The resulting hydrochloride was dissolved in CHCl_3 (10 mL) and sat. aq. solution of NaHCO_3 (10 mL) was added. The biphasic mixture was vigorously stirred for 30 min. Then organic phase was separated, dried over MgSO_4 , and evaporated to give a bright-orange solid (951.6 mg, 10%). mp 57.8–59.1 °C (*n*-heptane); IR (film) 3494, 3370, 1664, 1622, 1587, 1539 cm^{-1} ; $^1\text{H NMR}$ (400 MHz, CDCl_3) δ 7.78 (s, 1H), 7.32 (dd, $J = 9.0, 2.4$ Hz, 1H), 6.69 (d, $J = 9.0$ Hz, 1H), 6.50 (br s, 2H); $^{13}\text{C NMR}$ (100 MHz, CDCl_3) δ 182.2 (t, $J_{\text{CF}} = 24.2$ Hz), 151.8, 136.9, 130.2–129.8 (m), 120.9, 119.2, signals in the region of 120–102 ppm has been omitted in description of spectra for clarity due to complicated multiplicity; $^{19}\text{F NMR}$ (376 MHz, CDCl_3) δ -79.8 (t, $J = 9.5$ Hz), -110.9 to -111.1 (m), -125.0 to -125.2 (m); HRMS (ESI-TOF) m/z $[\text{M} + \text{H}]^+$ Calcd for $\text{C}_{10}\text{H}_6\text{F}_7\text{ClNO}$ 324.0026, found 324.0019.

1-(2-Amino-5-chlorophenyl)-2,2-difluoroethanone (1k). To a solution of *N*-(4-chlorophenyl)-2,2-dimethylpropanamide (10.0 g, 44.7 mmol) and TMEDA (44.7 mmol, 6.8 mL, 2.0 equiv) in THF (100 mL), cooled to -40 °C, *n*-BuLi (39.3 mL, 98.3 mmol, 2.2 equiv, 2.5 M in hexane) was added dropwise by means of syringe pump within 30 min (temp. has increased to -25 °C), and the reaction was stirred for 2 h at 0 to -5 °C degree (internal temperature; reaction mixture was stirred by means of mechanical stirrer due to lithium dianion precipitation). Then reaction mixture was cooled to -40 °C and 2,2-difluoro-1-(morpholin-4-yl)ethanone (10.3 g, 62.6 mmol, 1.4 equiv) was added (the internal temp. has risen to -15 °C). Then reaction mixture was allowed to stir below 0 °C for additional 1 h and quenched with 10% citric acid (100 mL). Then mixture was diluted with EtOAc (100 mL), and aqueous phase was separated and extracted with EtOAc (2×50 mL). The combined organic phases were washed with brine (2×100 mL), dried over MgSO_4 , evaporated. The residue was chromatographed on silica (5% EtOAc/hexanes) to give amide containing some impurities which was used in the next step without further purification.

The obtained *o*-TFMK derivative was treated with 36% HCl (40 mL) and the resulting mixture was heated at 90 °C for 16 h. Then reaction mixture was quenched with sat. solution of Na_2CO_3 (100 mL), and aqueous phase was extracted with MTBE (3×30 mL). The combined organic phases were washed with brine (2×100 mL), dried over MgSO_4 , and evaporated. The residue crystallized from *n*-heptane (15 mL) to give an orange solid (3.13 g). The mother liquid was evaporated and the resulting solid was recrystallized from *n*-heptane to give additional portion of ketone **1k** (567.7 mg, summary yield 39%). $^1\text{H NMR}$ (400 MHz, CDCl_3) δ 7.80–7.40 (m, 1H), 7.29 (dd, $J_{\text{CF}} = 9.0, 2.4$ Hz, 1H), 6.57 (d, $J_{\text{CF}} = 9.0$ Hz, 1H), 6.39 (br s, 2H, NH) overlapping 6.28 (t, $J_{\text{CF}} = 53.6$ Hz, 1H, CF_2H). Spectral data are in agreement with those reported.⁵⁹

1-(2-Aminopyridin-3-yl)-2,2,2-trifluoroethanone (6a). To a solution of 2,2-dimethyl-*N*-(pyridin-2-yl)propanamide amide (5 g, 28.05 mmol) and TMEDA (56.11 mmol, 8.6 mL, 2.0 equiv) in THF (50 mL), cooled to -60 °C, *n*-BuLi (24.6 mL, 56.11 mmol, 2.2 equiv, 2.28 M in hexane) was added dropwise by means of syringe pump within 30 min (temp. has increased to -50 °C), and the reaction was stirred for 4 h at 0 to -5 °C degree (internal temperature; reaction mixture was stirred by means of mechanical stirrer due to lithium dianion precipitation). Then reaction mixture was cooled to -65 °C and $\text{CF}_3\text{CO}_2\text{Et}$ (4.67 mL, 39.27 mmol, 1.4 equiv) was added (the internal temp. has risen to -45 °C). Then cooling bath was removed, and the reaction mixture was allowed to warm up to -20 °C (exothermic reaction begins at -35 °C) and stirred for additional 30 min and quenched with sat. NH_4Cl (100 mL). Then mixture was diluted with EtOAc (150 mL), and organic phase was separated, washed with citric acid (1×100 mL), brine (2×100 mL), dried over MgSO_4 and evaporated. The residue was chromatographed on silica (25–60% EtOAc/hexanes) to give yellow solid (4.68 g). $^1\text{H NMR}$ indicated

some impurities and thus obtained pyridine derivative was used in the next step without further purification.

The crude pyridine derivative was treated with HCl in dioxane (20 mL, 4 M in dioxane) and water (2 mL) and the resulting mixture was heated at 90 °C for 16 h. Then reaction mixture was quenched with sat. solution of NaHCO₃ (100 mL), and the aqueous phase was extracted with EtOAc (3 × 50 mL). The combined organic phases were washed with brine (2 × 100 mL), dried over MgSO₄, and evaporated. The residue was crystallized (*n*-heptane, to remove partially contaminations) and then was passed through pad of silica (10% MeOH/DCM) to give a yellow solid (2.45 g, 46%). ¹H NMR (400 MHz, CDCl₃) δ 8.35 (dd, *J* = 4.6, 1.8 Hz, 1H), 8.10–8.04 (m, 1H), 7.17 (br s, 2H), 6.70 (dd, *J* = 20.2, 4.6 Hz, 1H); ¹³C NMR (100 MHz, CDCl₃) δ 180.1 (q, *J*_{CF} = 33.8 Hz), 160.4, 156.8, 140.5 (q, *J*_{CF} = 4.0 Hz), 114.8 (q, *J*_{CF} = 289.5 Hz), 112.8, 106.4; ¹⁹F NMR (376 MHz, CDCl₃) δ -69.2. CAS registry number 1060801-31-1; no spectroscopic data are available for comparison. Copy of spectra are included in this [Experimental Section](#).

1-(4-Aminopyridin-3-yl)-2,2,2-trifluoroethanone (6b). To a solution 2,2-dimethyl-*N*-(pyridin-4-yl)propanamide (4.04 g, 22.66 mmol) TMEDA (45.34 mmol, 6.95 mL) amide in THF (40), cooled to -60 °C, *n*-BuLi (19.9 mL, 45.34 mmol, 2.2 equiv, 2.28 M in hexane) was added dropwise by means of syringe pump within 30 min. (temp. has increased to -50 °C), and the reaction was stirred for 4 h at 0 to -5 °C degree (internal temperature; reaction mixture was stirred by means of mechanical stirrer due to lithium dianion precipitation). Then reaction mixture was cooled to -65 °C and CF₃CO₂Et (3.77 mL, 31.73 mmol, 1.4 equiv) was added (the internal temp. has risen to -35 °C). Then cooling bath was removed, and the reaction mixture was allowed to warm up to -10 °C and stirred for additional 1 h and quenched with 10% citric acid (100 mL). Then mixture was diluted with EtOAc (100 mL), and aqueous phase was extracted with EtOAc (2 × 50 mL). The combined organic phases were washed with brine (2 × 100 mL), dried over MgSO₄, evaporated and dried in vacuo to give a yellow foam (6.1 g) which was used in the next step without further purification.

The crude pyridine derivative was treated with HCl in dioxane (20 mL, 4 M in dioxane) and water (2 mL) and the resulting mixture was heated at 90 °C for 16 h. Then reaction mixture was quenched with sat. solution of Na₂CO₃ (100 mL), and aqueous phase was extracted with EtOAc (3 × 50 mL). The combined organic phases were washed with brine (2 × 100 mL), dried over MgSO₄, and evaporated. The residue purified by chromatography (5–10% MeOH/DCM) and further crystallized (toluene/*n*-heptane = 50:50) to give a brown-orange solid (2.99 g, 69%). ¹H NMR (400 MHz, CDCl₃) δ 8.93–8.86 (m, 1H), 8.25 (d, *J* = 6.0 Hz, 1H), 6.61 (d, *J* = 6.0 Hz, 1H), (NH₂ group was exchange with deuterium); ¹³C NMR (100 MHz, CDCl₃) δ 181.3 (q, *J*_{CF} = 35.2 Hz), 156.4, 154.1 (q, *J*_{CF} = 5.2 Hz), 153.0, 116.5 (q, *J*_{CF} = 289.0 Hz), 111.5, 109.3; ¹⁹F NMR (376 MHz, CDCl₃) δ -70.1 CAS registry number: 1343447-95-9; no spectra available for comparison. Copy of spectra are included in this [Experimental Section](#).

1-(2-Amino-5-chloropyridin-3-yl)-2,2,2-trifluoroethanone (6c). To a solution of *N*-(5-chloropyridin-2-yl)-2,2-dimethylpropanamide (5.0 g, 23.51 mmol) in MTBE (50 mL) and TMEDA (3.6 mL, 23.51 mmol, 1.0 equiv), cooled to -35 °C, a solution of *n*-BuLi (20.7 mL, 51.72 mmol, 2.2 equiv, 2.5 M in hexanes) was added dropwise by means of syringe pump within 1 h while the temperature was kept below -20 °C. The mixture was aged at 0–5 °C for 2 h (a light-orange solid has been formed), cooled to -45 °C, and CF₃CO₂Et (3.92 mL, 32.91 mmol, 1.4 equiv) was added rapidly (internal temp. reached -10 °C). Then reaction mixture was stirred for 16 h at rt and quenched with 5% HCl (100 mL). Then reaction mixture was stirred for 16 h at rt and quenched with 5% HCl (50 mL). The organic phase was separated and the aqueous phase was extracted with EtOAc (3 × 20 mL). Then combined organic phases were washed with brine (1 × 100 mL), dried over MgSO₄ and evaporated. The residue was chromatographed on silica (25% EtOAc/hexanes–EtOAc) to give an orange solid (3.96 g). ¹H NMR indicated some impurities and thus obtained aminofluoroketone was used in the next step without further purification.

The crude aminopyridine was treated with 36% HCl (30 mL) at rt and stirred for 16 h at 90 °C (temp. of oil bath, a white solid has been formed). Then reaction mixture was cooled to rt, neutralized with sat. solution of Na₂CO₃ (pH = 9) and extracted with EtOAc (4 × 30 mL). The combined organic extracts were washed with brine (1 × 30 mL), dried over MgSO₄, and evaporated. The residue was chromatographed on silica to give a yellow solid (1.15 g, 22%). ¹H NMR (400 MHz, CDCl₃) δ 8.31 (d, *J* = 2.5 Hz, 1H), 8.02–7.99 (m, 1H), 7.09 (br s, 2H); ¹³C NMR (100 MHz, CDCl₃) δ 179.5 (q, *J*_{CF} = 34.8 Hz), 158.5, 155.7, 137.9 (q, *J*_{CF} = 4.2 Hz), 119.2, 116.6 (q, *J*_{CF} = 289.3 Hz), 106.4; ¹⁹F NMR (376 MHz, CDCl₃) δ -70.1. Spectral data are in agreement with those reported.⁶³

General Procedure for Synthesis of Quinoline and Naphthyrine Derivatives. To a screw-cap vial, trifluoromethylketone (TFMK), alkyne (1.2 equiv), copper catalyst (2 mol %) and DME (100 μL) were added. The obtained mixture was stirred at rt (2–3 min) until complete dissolution of the substrates. Then, a solution of TMG (*N,N,N',N'*-tetramethylguanidine, 0.01 mmol, 2 mol %) in degassed water (2 mL) was added. The biphasic mixture was stirred for the indicated time at 100–120 °C (oil bath temp.) with vigorous stirring. Next, the reaction mixture was diluted with EtOAc (2–3 mL), and the aqueous phase was separated and extracted with two additional portions of EtOAc. The combined extracts were washed with brine (1 × 10 mL), dried over MgSO₄ and evaporated. The residue was chromatographed on silica (silica: crude reaction mixture = 30:1 w/w) using an appropriate eluting system to afford the product.

6-Chloro-2-cyclopropyl-4-(trifluoromethyl)quinoline (3a). Title compound was obtained according to the general procedure from ketone **1a** (223.6 mg, 1.0 mmol), TMG (2.5 μL, 0.02 mmol, 2 mol %), ethynylcyclopropane (**2a**) (134.0 μL, 1.2 mmol, 1.2 equiv), IPr*CuCl (20.2 mg, 0.02 mmol, 2 mol %), water (2 mL) and DME (0.1 mL). The crude product was chromatographed on silica (2% EtOAc/hexanes) to give a colorless oil which spontaneously solidified upon standing in the fridge (96.4 mg, 71%). ¹H NMR (400 MHz, CDCl₃) δ 8.03–7.99 (m, 1H), 7.94 (dd, *J* = 9.0, 0.3 Hz, 1H), 7.65 (dd, *J* = 9.0, 2.2 Hz, 1H), 7.54 (s, 1H), 2.29–2.21 (m, 1H), 1.27–1.21 (m, 2H), 1.18–1.11 (m, 2H). ¹H NMR data are in agreement with those reported.⁶⁴

Gram-scale preparation of **3a** was conducted according to the general procedure with ketone **1a** (1.12 g, 5.0 mmol), TMG (12.5 μL, 0.1 mmol, 2 mol %), ethynylcyclopropane (**2a**) (0.5 mL, 6.0 mmol, 1.2 equiv), IPr*CuCl (101.2 mg, 0.1 mmol, 2 mol %), water (10 mL) and DME (0.5 mL). The crude product was chromatographed on silica (2% EtOAc/hexanes) to give quinolone **3a** (1.032 g, 76%) and diazocine **4a** (75.1 mg, 7%).

6-Chloro-2-phenyl-4-(trifluoromethyl)quinoline (3b). Title compound was obtained according to the general procedure from ketone **1a** (111.8 mg, 0.5 mmol), TMG (1.25 μL, 0.01 mmol, 2 mol %), ethynylbenzene (**2b**) (67.0 μL, 0.6 mmol, 1.2 equiv), IPr*CuCl (10.2 mg, 0.01 mmol, 2 mol %), DME (100 μL) and water (2 mL). The reaction mixture was heated at 100 °C for 16 h. The crude product was chromatographed on silica (2% EtOAc/hexanes) to give a colorless oil (66.6 mg, 43%). IR (KBr) 3094, 3063, 3038, 1610, 1550, 1152, 1121 cm⁻¹; ¹H NMR (400 MHz, CDCl₃) δ 8.22–8.15 (m, 4H), 8.13–8.09 (m, 1H), 7.75 (dd, *J* = 9.0, 2.2 Hz, 1H), 7.60–7.49 (m, 3H); ¹³C NMR (100 MHz, CDCl₃) δ 156.8, 147.5, 137.9, 134.3 (q, *J*_{CF} = 31.7 Hz), 134.0, 132.1, 131.4, 130.3, 129.1, 127.4, 123.3 (q, *J*_{CF} = 273.1 Hz), 122.9 (q, *J*_{CF} = 2.3 Hz), 122.4, 116.7 (q, *J*_{CF} = 5.2 Hz); ¹⁹F NMR (376 MHz) δ -61.7; HRMS (ESI-TOF) *m/z* [M + H]⁺ Calcd for C₁₆H₁₀ClF₃N 308.0454, found 308.0455.

6-Chloro-2-(4-methoxyphenyl)-4-(trifluoromethyl)quinoline (3c). Title compound was obtained according to the general procedure from ketone **1a** (111.8 mg, 0.5 mmol), TMG (1.25 μL, 0.01 mmol, 2 mol %), 1-ethynyl-4-methoxybenzene (**2c**) (78.0 μL, 0.6 mmol, 1.2 equiv), IPr*CuCl (10.2 mg, 0.01 mmol, 2 mol %), DME (100 μL) and water (2 mL). The reaction mixture was heated at 100 °C for 16 h. The crude product was chromatographed on silica (2% EtOAc/hexanes) to give a colorless oil (107.6 mg, 64%). IR (KBr) 3070, 2967, 2938, 2917, 2840, 1610, 1546, 1148, 1121 cm⁻¹; ¹H NMR (400 MHz, CDCl₃) δ 8.18–8.10 (m, 4H), 8.09–8.04 (m, 1H), 7.71 (dd, *J* = 9.0, 2.2 Hz,

1H), 7.09–7.02 (m, 2H), 3.90 (s, 3H); ¹³C NMR (100 MHz, CDCl₃) δ 161.6, 156.3, 147.5, 134.1 (q, *J*_{CF} = 31.6 Hz), 133.4, 131.8, 131.3, 130.5, 128.9, 123.3 (q, *J*_{CF} = 273.2 Hz), 122.9 (q, *J*_{CF} = 2.2 Hz), 122.0, 116.2 (q, *J*_{CF} = 5.3 Hz), 114.5, 55.4; ¹⁹F NMR (376 MHz) δ –61.7; HRMS (ESI-TOF) *m/z* [M + H]⁺ Calcd for C₁₇H₁₂ClF₃NO 338.0560, found 338.0561.

6-Chloro-4-(trifluoromethyl)-2-(3,4,5-trimethoxyphenyl)quinoline (3d). Title compound was obtained according to the general procedure from ketone **1a** (111.8 mg, 0.5 mmol), TMG (1.25 μL, 0.01 mmol, 2 mol %), 1-ethynyl-3,4,5-trimethoxybenzene (**2d**) (115.0 mg, 0.6 mmol, 1.2 equiv), IPr^{*}CuCl (10.2 mg, 0.01 mmol, 2 mol %), DME (100 μL) and water (2 mL). The reaction mixture was heated at 100 °C for 16 h. The crude product was chromatographed on silica (5% EtOAc/toluene) to give a colorless oil which spontaneously solidified upon standing in the fridge (106.0 mg, 53%). mp 134.5–136.5 °C; IR (KBr) 3097, 2937, 2842, 1581, 1167, 1126 cm⁻¹; ¹H NMR (400 MHz, CDCl₃) δ 8.18 (d, *J* = 8.8 Hz, 1H), 8.13–8.05 (m, 2H), (dd, *J* = 9.0, 2.2 Hz, 1H), 7.40 (br s, 2H), 4.02 (s, 6H), 3.94 (s, 3H); ¹³C NMR (100 MHz, CDCl₃) δ 156.4, 153.8, 147.4, 140.5, 134.4 (q, *J*_{CF} = 31.7 Hz), 133.9, 133.4, 132.0, 131.5, 123.3 (q, *J*_{CF} = 273.1 Hz), 122.9 (q, *J*_{CF} = 2.4 Hz), 122.3 (q, *J*_{CF} = 1.1 Hz), 116.7 (q, *J*_{CF} = 5.2 Hz), 104.9, 61.0, 56.4; ¹⁹F NMR (376 MHz) δ –61.6; HRMS (ESI-TOF) *m/z* [M + H]⁺ Calcd for C₁₉H₁₆ClF₃NO₃ 398.0771, found 398.0769.

6-Chloro-2-(4-methylphenyl)-4-(trifluoromethyl)quinoline (3e). Title compound was obtained according to the general procedure from ketone **1a** (111.8 mg, 0.5 mmol), TMG (1.25 μL, 0.01 mmol, 2 mol %), 1-ethynyl-4-methylbenzene (**2e**) (76.1 μL, 0.6 mmol, 1.2 equiv), IPr^{*}CuCl (10.2 mg, 0.01 mmol, 2 mol %), DME (100 μL) and water (2 mL). The reaction mixture was heated at 100 °C for 16 h. The crude product was chromatographed on silica (2.5% EtOAc/hexanes) to give a colorless oil which spontaneously solidified upon standing in the fridge (109.8 mg, 77%). ¹H NMR (400 MHz, CDCl₃) δ 8.19–8.15 (m, 2H), 8.11–8.06 (m, 3H), 7.74 (dd, *J* = 9.0, 2.2 Hz, 1H), 7.38–7.33 (m, 2H), 2.45 (s, 3H); ¹³C NMR (100 MHz, CDCl₃) δ 156.7, 147.5, 140.6, 135.1, 134.1 (q, *J*_{CF} = 31.6 Hz), 133.7, 132.0, 131.2, 129.8, 127.3 (q, *J*_{CF} = 273.1 Hz), 129.9 (q, *J*_{CF} = 2.3 Hz), 122.2, 116.5 (q, *J*_{CF} = 5.2 Hz), 21.4; ¹⁹F NMR (376 MHz) δ –61.7. ¹H NMR data are in agreement with those reported.²² ¹³C NMR spectra are described by the authors without C–F coupling constants and the accurate description is provided above. A copy of the spectra is included in the SI.

6-Chloro-2-(pyridin-3-yl)-4-(trifluoromethyl)quinoline (3f). Title compound was obtained according to the general procedure from ketone **1a** (111.8 mg, 0.5 mmol), TMG (1.25 μL, 0.01 mmol, 2 mol %), 3-ethynylpyridine (**2f**) (62.0 mg, 0.6 mmol, 1.2 equiv), IPr^{*}CuCl (10.2 mg, 0.01 mmol, 2 mol %), DME (100 μL) and water (2 mL). The reaction mixture was heated at 100 °C for 16 h. The crude product was chromatographed on silica (25% EtOAc/hexanes) to give a colorless oil which spontaneously solidified upon standing in the fridge (17.8 mg, 11%). mp 157.2–157.5 °C; IR (film) 3059, 1613, 1126 cm⁻¹; ¹H NMR (400 MHz, CDCl₃) δ 9.41 (br s, 1H), 8.78 (br s, 1H), 8.50 (d, *J* = 8.0 Hz, 1H), 8.24–8.16 (m, 2H), 8.15–8.10 (m, 1H), 7.78 (dd, *J* = 9.2, 2.0 Hz, 1H), 7.55–7.44 (m, 1H); ¹³C NMR (100 MHz, CDCl₃) δ 154.3, 151.1, 148.7, 147.6, 134.8 (q, *J*_{CF} = 31.9 Hz), 134.7, 134.7, 132.2, 131.8, 123.9 (m), 123.1 (q, *J*_{CF} = 273.2 Hz), 123.0 (q, *J*_{CF} = 2.3 Hz), 122.6, 116.2 (q, *J*_{CF} = 5.2 Hz); ¹⁹F NMR (376 MHz) δ –61.7; HRMS (EI) *m/z* [M⁺] Calcd for C₁₅H₈ClF₃N₂ 308.0328, found 308.0321.

6-Chloro-2-(thiophen-3-yl)-4-(trifluoromethyl)quinoline (3g). Title compound was obtained according to the general procedure from ketone **1a** (111.8 mg, 0.5 mmol), TMG (1.25 μL, 0.01 mmol, 2 mol %), 3-ethynylthiophene (**2g**) (59.0 μL, 0.6 mmol, 1.2 equiv), IPr^{*}CuCl (10.2 mg, 0.01 mmol, 2 mol %), DME (100 μL) and water (2 mL). The reaction mixture was heated at 100 °C for 16 h. The crude product was chromatographed on silica (3% EtOAc/hexanes) to give a colorless oil which spontaneously solidified upon standing in the fridge (84.1 mg, 53%). mp 145.0–146.0 °C; IR (KBr) 3095, 1641, 1554, 1148, 1119 cm⁻¹; ¹H NMR (400 MHz, CDCl₃) δ 8.19–8.00 (m, 4H), 7.86 (dd, *J* = 5.1, 1.2 Hz, 1H), 7.71 (dd, *J* = 9.0, 2.2 Hz, 1H), 7.47 (q, *J* = 5.1, 2.2 Hz, 1H); ¹³C NMR (100 MHz, CDCl₃) δ 152.7, 147.5,

141.2, 134.2 (q, *J*_{CF} = 31.7 Hz), 133.7, 131.8, 131.4, 127.0, 126.5, 125.8, 123.2 (q, *J*_{CF} = 273.2 Hz), 123.0 (q, *J*_{CF} = 2.2 Hz), 122.2, 116.9 (q, *J*_{CF} = 5.3 Hz); ¹⁹F NMR (376 MHz) δ –61.8; HRMS (ESI-TOF) *m/z* [M + H]⁺ Calcd for C₁₄H₈ClF₃Na 314.0018, found 314.0017.

6-Chloro-2-(cyclohex-1-en-1-yl)-4-(trifluoromethyl)quinoline (3h). Title compound was obtained according to the general procedure from ketone **1a** (111.8 mg, 0.5 mmol), TMG (1.25 μL, 0.01 mmol, 2 mol %), 1-ethynylcyclohexene (**2h**) (70.5 μL, 0.6 mmol, 1.2 equiv), IPr^{*}CuCl (10.2 mg, 0.01 mmol, 2 mol %), DME (100 μL) and water (2 mL). The reaction mixture was heated at 100 °C for 16 h. The crude product was chromatographed on silica (3% EtOAc/hexanes) to give a colorless oil which spontaneously solidified upon standing in the fridge (114.1 mg, 73%). mp 101.8–105.2 °C; IR (KBr) 3048, 2942, 2910, 2832, 1632, 1612, 1550, 1153, 1125 cm⁻¹; ¹H NMR (400 MHz, CDCl₃) δ 8.08–8.00 (m, 2H), 7.90 (br s, 1H), 7.70–7.64 (m, 1H), 6.88–6.83 (m, 1H), 2.73–2.65 (m, 2H), 2.39–2.31 (m, 2H), 1.89–1.80 (m, 2H), 1.78–1.69 (m, 2H); ¹³C NMR (100 MHz, CDCl₃) δ 158.4, 147.0, 137.0, 133.4 (q, *J*_{CF} = 31.4 Hz), 133.2, 132.4, 131.8, 130.9, 123.4 (q, *J*_{CF} = 272.2 Hz), 122.8 (q, *J*_{CF} = 2.3 Hz), 122.0, 115.8 (q, *J*_{CF} = 5.3 Hz), 26.3, 25.6, 22.6, 22.0; ¹⁹F NMR (376 MHz) δ –61.8; HRMS (ESI-TOF) *m/z* [M + H]⁺ Calcd for C₁₆H₁₄ClF₃N 312.0767, found 312.0768.

6-Chloro-4-(trifluoromethyl)-2-[4-(trifluoromethyl)phenyl] (3i). Title compound was obtained according to the general procedure from ketone **1a** (111.8 mg, 0.5 mmol), TMG (1.25 μL, 0.01 mmol, 2 mol %), 1-ethynyl-4-trifluoromethylbenzene (**2i**) (98.0 μL, 0.6 mmol, 1.2 equiv), IPr^{*}CuCl (10.2 mg, 0.01 mmol, 2 mol %), DME (100 μL) and water (2 mL). The reaction mixture was heated at 100 °C for 16 h. The crude product was chromatographed on silica (2% EtOAc/hexanes) to give a colorless oil which spontaneously solidified upon standing in the fridge (29.0 mg, 15%). mp 165.5–166.8 °C; IR (KBr) 3070, 2967, 2938, 2916, 2840, 1610, 1546, 1149, 1121 cm⁻¹; ¹H NMR (400 MHz, CDCl₃) δ 8.30 (br d, *J* = 8.2 Hz, 2H), 8.24–8.16 (m, 2H), 8.15–8.11 (m, 1H), 7.84–7.75 (m, 3H); ¹³C NMR (100 MHz, CDCl₃) δ 155.1, 147.5, 141.1, 134.8, 134.7 (q, *J*_{CF} = 31.9 Hz), 132.5, 132.1 (q, *J*_{CF} = 32.4 Hz), 131.8, 127.8, 126.0 (q, *J*_{CF} = 3.8 Hz), 124.0 (q, *J*_{CF} = 270.1 Hz), 123.2 (q, *J*_{CF} = 273.1 Hz), 123.0 (q, *J*_{CF} = 2.4 Hz), 122.7, 116.5 (q, *J*_{CF} = 5.3 Hz); ¹⁹F NMR (376 MHz) δ –61.7, –62.8; HRMS (ESI-TOF) *m/z* [M + H]⁺ Calcd for C₁₇H₈ClF₆N 376.0328, found 376.0323.

6-Chloro-2-hexyl-4-(trifluoromethyl)quinoline (3j). Title compound was obtained according to the general procedure from ketone **1a** (111.8 mg, 0.5 mmol), TMG (1.25 μL, 0.01 mmol, 2 mol %), 1-octyne (**2j**) (88.5 μL, 0.6 mmol, 1.2 equiv), IPr^{*}CuCl (10.2 mg, 0.01 mmol, 2 mol %), DME (100 μL) and water (2 mL). The reaction mixture was heated at 100 °C for 16 h. The crude product was chromatographed on silica (2% EtOAc/hexanes) to give a colorless oil (110.6 mg, 70%). IR (film) 2957, 2929, 2858, 1613, 1164, 1137 cm⁻¹; ¹H NMR (400 MHz, CDCl₃) δ 8.09–8.03 (m, 2H), 7.70 (dd, *J* = 9.0, 2.4 Hz, 1H), 7.59 (br s, 1H), 3.01 (t, *J* = 7.6 Hz, 2H), 1.91–1.74 (m, 2H), 1.52–1.21 (m, 6H), 0.89 (t, *J* = 6.8 Hz, 3H); ¹³C NMR (100 MHz, CDCl₃) δ 162.8, 147.2, 133.6 (q, *J*_{CF} = 31.7 Hz), 133.4, 131.3, 131.0, 123.3 (q, *J*_{CF} = 273.0 Hz), 122.9 (q, *J*_{CF} = 2.3 Hz), 122.0, 119.2 (q, *J*_{CF} = 5.1 Hz), 39.2, 31.6, 29.5, 29.1, 22.5, 14.0; ¹⁹F NMR (376 MHz) δ –61.7; HRMS (ESI-TOF) *m/z* [M + H]⁺ Calcd for C₁₆H₁₈ClF₃N 316.1080, found 316.1080.

6-Chloro-2-(2-methylpropyl)-4-(trifluoromethyl)quinoline (3k). Title compound was obtained according to the general procedure from ketone **1a** (111.8 mg, 0.5 mmol), TMG (1.25 μL, 0.01 mmol, 2 mol %), 4-methylpent-1-yne (**2k**) (70.5 μL, 0.6 mmol, 1.2 equiv), IPr^{*}CuCl (10.2 mg, 0.01 mmol, 2 mol %), DME (100 μL) and water (2 mL). The reaction mixture was heated at 100 °C for 16 h. The crude product was chromatographed on silica (5% EtOAc/hexanes) to give a colorless oil which spontaneously solidified upon standing in the fridge (87.4 mg, 61%). mp 56.0–58.0 °C; IR (KBr) 3107, 3071, 2958, 2872, 1608, 1154, 1126 cm⁻¹; ¹H NMR (400 MHz, CDCl₃) δ 8.11–8.02 (m, 2H), 7.70 (dd, *J* = 9.0, 2.2 Hz, 1H), 7.56 (s, 1H), 2.89 (d, *J* = 7.6 Hz, 2H), 2.24 (hept, *J* = 6.8 Hz, 1H), 0.99 (d, *J* = 6.4 Hz, 6H); ¹³C NMR (100 MHz, CDCl₃) δ 162.0, 147.2, 133.4 (q, *J*_{CF} = 31.7 Hz), 134.4, 131.4, 131.0, 123.2 (q, *J*_{CF} = 273.0 Hz), 122.9 (q, *J*_{CF} = 2.3 Hz),

122.0, 119.6 (q, $J_{CF} = 5.1$ Hz), 48.1, 29.2, 22.5; ^{19}F NMR (376 MHz) δ -61.7; HRMS (ESI-TOF) m/z $[\text{M} + \text{H}]^+$ Calcd for $\text{C}_{14}\text{H}_{14}\text{ClF}_3\text{N}$ 288.0767, found 288.0768.

3-[6-Chloro-4-(trifluoromethyl)quinolin-2-yl]propan-1-ol (3l). Title compound was obtained according to the general procedure from ketone **1a** (111.8 mg, 0.5 mmol), TMG (1.25 μL , 0.01 mmol, 2 mol %), pent-4-yn-1-ol (**2l**) (50.4 mg, 0.6 mmol, 1.2 equiv), IPr^*CuCl (10.2 mg, 0.01 mmol, 2 mol %), DME (100 μL) and water (2 mL). The reaction mixture was heated at 100 °C for 16 h. The crude product was chromatographed on silica (40–50% EtOAc/hexanes) to give a colorless oil which spontaneously solidified upon standing in the fridge (104.9 mg, 68%). mp 94.0–95.0 °C; IR (KBr) 3374, 3296, 3097, 3067, 3039, 2964, 2893, 1617, 1557, 1152, 1124 cm^{-1} ; ^1H NMR (400 MHz, CDCl_3) δ 8.08–8.01 (m, 2H), 7.71 (dd, $J = 9.0, 2.2$ Hz, 1H), 7.63 (br s, 1H), 3.77 (t, $J = 6.0$ Hz, 2H), 3.19 (t, $J = 7.1$ Hz, 2H), 2.18–2.08 (m, 2H); ^{13}C NMR (100 MHz, CDCl_3) δ 162.0, 146.7, 134.0 (q, $J_{CF} = 31.8$ Hz), 133.7, 131.3, 131.0, 123.1 (q, $J_{CF} = 273.4$ Hz), 122.9 (q, $J_{CF} = 2.3$ Hz), 122.0, 119.5 (q, $J_{CF} = 5.0$ Hz), 62.0, 35.8, 31.1; ^{19}F NMR (376 MHz) δ -61.7; HRMS (ESI-TOF) m/z $[\text{M} + \text{H}]^+$ calcd for $\text{C}_{13}\text{H}_{12}\text{ClF}_3\text{NO}$ 290.0560, found 290.0555.

Methyl 4-[6-chloro-4-(trifluoromethyl)quinolin-2-yl]butanoate (3m). Title compound was obtained according to the general procedure from ketone **1a** (111.8 mg, 0.5 mmol), TMG (1.25 μL , 0.01 mmol, 2 mol %), methyl hex-5-ynoate (**2m**) (74.0 mg, 0.6 mmol, 1.2 equiv), IPr^*CuCl (10.2 mg, 0.01 mmol, 2 mol %), DME (100 μL) and water (2 mL). The reaction mixture was heated at 100 °C for 16 h. The crude product was chromatographed on silica (5% EtOAc/toluene) to give a colorless oil which spontaneously solidified upon standing in the fridge (82.7 mg, 50%). mp 54.0–56.0 °C; IR (KBr) 3077, 2973, 2954, 2921, 2898, 2852, 1732, 1620, 1560, 1146, 1125 cm^{-1} ; ^1H NMR (400 MHz, CDCl_3) δ 8.10–8.02 (m, 2H), 7.71 (dd, $J = 9.0, 2.2$ Hz, 1H); 7.60 (s, 1H), 3.67 (s, 3H), 3.07 (t, $J = 7.6$ Hz, 2H), 2.46 (t, $J = 7.4$ Hz, 2H), 2.26–2.14 (m, 2H); ^{13}C NMR (100 MHz, CDCl_3) δ 173.5, 161.4, 147.1, 133.8 (q, $J_{CF} = 31.8$ Hz), 133.6, 131.4, 131.2, 123.2 (q, $J_{CF} = 273.1$ Hz), 122.9 (q, $J_{CF} = 2.4$ Hz), 122.1 (q, $J_{CF} = 1.2$ Hz), 119.2 (q, $J_{CF} = 5.1$ Hz), 51.6, 38.0, 33.3, 24.1; ^{19}F NMR (376 MHz) δ -61.7; HRMS (ESI-TOF) m/z $[\text{M} + \text{H}]^+$ Calcd for $\text{C}_{15}\text{H}_{14}\text{ClF}_3\text{NO}_2$ 332.0665, found 332.0666.

6-Chloro-2-(3-[[3aS,4S,5aR,9aR,9bS)-2,2,8,8-tetramethylhexahydro[1,3]dioxolo[4,5]pyrano[3,2-d][1,3]dioxin-4-yl]oxy]propyl)-4-(trifluoromethyl)quinoline (3n). Title compound was prepared according to the general procedure from *o*-TFMK **1a** (111.8 mg, 0.5 mmol), (3aS,4S,5aR,9aR,9bS)-2,2,8,8-Tetramethyl-4-(pent-4-yn-1-yloxy)hexahydro[1,3]dioxolo[4,5]pyrano [3,2-d][1,3]dioxine (**2n**) (163.1 mg, 0.5 mmol), IPr^*CuCl (10.1 mg, 0.00005 mmol, 2 mol %), TMG (1.25 μL , 0.00005 mmol, 2 mol %), DME (100 μL) and water (2 mL). Reaction mixture was heated at 100 °C for 24 h. Then reaction mixture was extracted with EtOAc (3 \times 10 mL), and the combined organic phases were washed with brine (1 \times 20 mL), dried over MgSO_4 and evaporated. The residue was chromatographed on silica (20–30% MTBE/hexanes) to give a light-yellow oil (181.4 mg, 68%). Purity based on HPLC: 99% (major peak 8.4 min, LiChrospher Si60 column, 250 mm \times 4.6 mm, 5 μm , DAD detector 209 nm, MTBE/hexane = 40:60; 1.0 mL/min); mp 95.5–96.4 °C; $[a]_D^{23} = 5.8$ (c = 1.1, CHCl_3); IR (film) 2991, 2938, 1613, 1496 cm^{-1} ; ^1H NMR (400 MHz, CDCl_3) δ 8.10–8.03 (m, 2H), 7.71 (dd, $J = 9.2, 2.4$ Hz, 1H), 7.61 (s, 1H), 5.0 (s, 1H), 4.11–4.05 (m, 2H), 3.86–3.77 (m, 2H), 3.77–3.68 (m, 2H), 3.61–3.48 (m, 2H), 3.12 (t, $J = 7.6$ Hz, 2H), 2.25–2.08 (m, 2H), 1.54 (s, 3H), 1.51 (s, 3H), 1.43 (s, 3H), 1.32 (s, 3H); ^{13}C NMR (100 MHz, CDCl_3) δ 161.7, 147.2, 133.8 (q, $J_{CF} = 31.7$ Hz), 133.6, 131.4, 131.2, 123.2 (q, $J_{CF} = 273.1$ Hz), 122.9 (q, $J_{CF} = 2.3$ Hz), 122.0, 119.2 (q, $J_{CF} = 5.1$ Hz), 109.4, 99.7, 97.9, 76.1, 74.9, 72.7, 66.9, 35.6, 29.0, 28.7, 28.2, 26.1, 18.8; ^{19}F NMR (376 MHz, CDCl_3) δ -61.7; HRMS (ESI-TOF) m/z $[\text{M} + \text{H}]^+$ Calcd for $\text{C}_{25}\text{H}_{30}\text{ClF}_3\text{NO}_6$ 532.1714, found 532.1703.

3-[6-Chloro-4-(trifluoromethyl)quinolin-2-yl]-1-(4-fluorophenyl)propan-1-one (3o). Title compound was obtained according to the general procedure from ketone **1a** (111.8 mg, 0.5 mmol), TMG (1.25 μL , 0.01 mmol, 2 mol %), 1-(4-Fluorophenyl)pent-4-yl-1-one (**2o**) (105.7 mg, 0.6 mmol, 1.2 equiv), IPr^*CuCl (10.2 mg, 0.01 mmol, 2

mol %), DME (100 μL) and water (2 mL). The reaction mixture was heated at 100 °C for 16 h. The crude product was chromatographed on silica (5% EtOAc/hexanes) to give a colorless oil which spontaneously solidified upon standing in the fridge (105.0 mg, 55%). mp 141.5–142.5 °C; IR (film) 3357, 3038, 3058, 2926, 1688, 1616, 1600, 1561 cm^{-1} ; ^1H NMR (400 MHz, CDCl_3) δ 8.11–8.01 (m, 3H), 7.93 (br d, $J = 9.2$ Hz, 1H), 7.71 (br s, 1H), 7.67 (dd, $J = 9.0, 2.0$ Hz, 1H), 7.19–7.10 (m, 2H), 3.63 (t, $J = 6.6$ Hz, 2H), 3.49 (t, $J = 6.6$ Hz, 2H); ^{13}C NMR (100 MHz, CDCl_3) δ 197.3, 165.8 (d, $J_{CF} = 253.1$ Hz), 160.7, 147.0, 133.6 (q, $J_{CF} = 31.8$ Hz), 133.5, 133.4 (d, $J_{CF} = 3.0$ Hz), 131.1 (d, $J_{CF} = 20.7$ Hz), 130.7 (d, $J_{CF} = 9.2$ Hz), 123.2 (q, $J_{CF} = 273.1$ Hz), 123.0 (q, $J_{CF} = 2.4$ Hz), 122.2, 119.9 (q, $J_{CF} = 5.2$ Hz), 115.7 (d, $J_{CF} = 21.7$ Hz), 36.2, 32.4; ^{19}F NMR (376 MHz) δ -61.7, -105.2; HR MS (ESI-TOF) m/z $[\text{M} + \text{H}]^+$ Calcd for $\text{C}_{19}\text{H}_{13}\text{ClF}_4\text{NO}$ 382.0619, found 382.0622.

4-[6-Chloro-4-(trifluoromethyl)quinolin-2-yl]-N-[(1S)-1-phenylethyl]butanamide (3p). Title compound was prepared according to the general procedure from *o*-TFMK **1a** (111.8 mg, 0.5 mmol), *N*-[(1S)-1-phenylethyl]hex-5-ynamide (**2p**) (129.2 mg, 0.6 mmol, 1.2 equiv), IPr^*CuCl (10.1 mg, 0.00005 mmol, 2 mol %), TMG (1.25 μL , 0.00005 mmol, 2 mol %), DME (100 μL) and water (2 mL). The reaction mixture was heated at 100 °C for 16 h. Then reaction mixture was extracted with EtOAc (3 \times 10 mL), and combined organic phases were washed with brine (1 \times 20 mL), dried over MgSO_4 and evaporated. The residue was chromatographed on silica (30–50% EtOAc/hexanes) to give a white solid (132.4 mg, 63%). mp 161.7–162.8 °C (*n*-heptane); $[a]_D^{23} = -26.2$ (c = 0.22, CHCl_3); IR (KBr) 3282, 3062, 2971, 2925, 2872, 1636, 1543 cm^{-1} ; ^1H NMR (400 MHz, CDCl_3) δ 8.07–8.03 (m, 1H), 7.93 (d, $J = 9.0$ Hz, 1H), 7.68 (dd, $J = 9.0, 2.2$ Hz, 1H), 7.59 (s, 1H), 7.37–7.22 (m, 5H), 6.25 (br d, $J = 7.4$ Hz, 1H), 5.20–5.10 (m, 1H), 3.05 (t, $J = 7.3$ Hz, 2H), 2.29–2.11 (m, 4H), 1.51 (d, $J = 6.9$ Hz, 3H); ^{13}C NMR (100 MHz, CDCl_3) δ 171.3, 161.6, 146.9, 143.3, 134.0 (q, $J_{CF} = 31.8$ Hz), 133.5, 131.2, 131.1, 128.6, 127.3, 126.2, 123.1 (q, $J_{CF} = 273.2$ Hz), 122.9 (q, $J_{CF} = 2.4$ Hz), 122.1, 119.4 (q, $J_{CF} = 5.1$ Hz), 48.8, 37.5, 35.4, 25.0, 21.7; ^{19}F NMR (376 MHz, CDCl_3) δ -61.7; HRMS (ESI-TOF) m/z $[\text{M} + \text{Na}]^+$ Calcd for $\text{C}_{22}\text{H}_{20}\text{ClF}_3\text{N}_2\text{ONa}$ 443.1114, found 443.1108.

3-[6-Chloro-4-(trifluoromethyl)quinolin-2-yl]propyl 2,3,4,6-tetra-O-acetyl- α -D-mannopyranoside (3q). Title compound was prepared according to the general procedure from *o*-TFMK **1a** (111.8 mg, 0.5 mmol), pent-4-yn-1-yl 2,3,4,6-tetra-O-acetyl- α -D-mannopyranoside (**2q**) (207.1 mg, 0.5 mmol), IPr^*CuCl (10.1 mg, 0.00005 mmol, 2 mol %), TMG (1.25 μL , 0.00005 mmol, 2 mol %), DME (100 μL) and water (2 mL). Reaction mixture was heated at 100 °C for 48 h. Then reaction mixture was extracted with EtOAc (3 \times 10 mL), and the combined organic phases were washed with brine (1 \times 20 mL), dried over MgSO_4 and evaporated. The residue was chromatographed on silica (40% MTBE/hexanes) to give a yellow oil (85.5 mg, 28%). Purity based on HPLC: 95% (major peak 6.8 min, LiChrospher Si60 column, 250 mm \times 4.6 mm, 5 μm , DAD detector 254 nm, MTBE/hexane = 20:80; 1.0 mL/min); $[a]_D^{23} = 32.7$ (c = 1.2, CHCl_3); IR (film) 2957, 2937, 1751, 1613 cm^{-1} ; ^1H NMR (400 MHz, CDCl_3) δ 8.08–8.02 (m, 2H), 7.71 (dd, $J = 9.1, 2.2$ Hz, 1H), 7.63 (br s, 1H), 5.34 (dd, $J = 10.0, 3.2$ Hz, 1H), 5.29 (dd, $J = 11.6, 9.6$ Hz, 1H), 5.25 (dd, $J = 3.2, 1.6$ Hz, 1H), 4.82 (d, $J = 1.6$ Hz, 1H), 4.25 (dd, $J = 12.0, 5.2$ Hz, 1H), 4.06 (dd, $J = 12.0, 2.4$ Hz, 1H), 3.97 (ddd, $J = 9.6, 5.2, 2.4$ Hz, 1H), 3.81 (dt, $J = 9.8, 6.4$ Hz, 1H), 3.57 (dt, $J = 9.8, 6.4$ Hz, 1H), 3.13 (t, $J = 7.6$ Hz, 2H), 2.27–2.16 (m, 2H), 2.15 (s, 3H), 2.04 (s, 3H), 2.02 (s, 3H), 1.99 (s, 3H); ^{13}C NMR (100 MHz, CDCl_3) δ 170.5, 170.0, 169.8, 169.7, 161.3, 147.1, 133.8 (q, $J_{CF} = 31.8$ Hz), 133.6, 131.3, 131.2, 123.1 (q, $J_{CF} = 273.2$ Hz), 122.9 (q, $J = 2.3$ Hz), 122.1, 119.3 (q, $J = 5.1$ Hz), 97.7, 69.6, 69.1, 68.6, 67.5, 66.2, 62.5, 35.2, 28.4, 20.8, 20.6, 20.6, 20.6; ^{19}F NMR (376 MHz, CDCl_3) δ -61.7; HRMS (ESI-TOF) m/z $[\text{M} + \text{Na}]^+$ Calcd for $\text{C}_{27}\text{H}_{29}\text{ClF}_3\text{NO}_{10}\text{Na}$ 642.1330, found 642.1315.

(3 β)-Cholest-5-en-3-yl 4-[6-chloro-4-(trifluoromethyl)quinolin-2-yl]butanoate (3r). Title compound was prepared according to the general procedure from *o*-TFMK **1a** (111.8 mg, 0.5 mmol), (3 β)-cholest-5-en-3-yl hex-5-ynoate (**2r**) (240.4 mg, 0.5 mmol), IPr^*CuCl (10.1 mg, 0.00005 mmol, 2 mol %), TMG (1.25 μL , 0.00005 mmol, 2

mol %), DME (100 μ L) and water (2 mL). Reaction mixture was heated at 100 $^{\circ}$ C for 16 h. Then reaction mixture was extracted with EtOAc (3 \times 10 mL), and the combined organic phases were washed with brine (1 \times 20 mL), dried over MgSO₄ and evaporated. The residue was chromatographed on silica (10% MTBE/hexanes) to give a yellow oil (286.3 mg, 83%). [a]_D²⁵ = -15.9 (c = 1.5, CHCl₃); Purity based on HPLC: 98% (major peak 8.6 min, LiChrospher Si60 column, 250 mm \times 4.6 mm, 5 μ m, DAD detector 208 nm, MTBE/hexane = 5:95; 1.0 mL/min); IR (film) 2948, 2868, 1732 cm⁻¹; ¹H NMR (400 MHz, CDCl₃) δ 8.11–8.05 (m, 2H), 7.71 (dd, *J* = 9.0, 2.1 Hz, 1H), 7.61 (s, 1H), 5.39–5.33 (m, 1H), 4.70–4.56 (m, 1H), 3.11–3.02 (m, 2H), 2.42 (t, *J* = 7.3 Hz, 2H), 2.35–2.27 (m, 2H), 2.24–2.12 (m, 2H), 2.06–1.76 (m, 5H), 1.65–1.08 (m, 21H) overlapping 1.01 (s, 3H), 0.91 (d, *J* = 6.5 Hz, 3H), 0.87 (d, *J* = 1.7 Hz, 3H), 0.87 (d, *J* = 1.7 Hz, 3H), 0.68 (s, 3H); ¹³C NMR (100 MHz, CDCl₃) δ 172.5, 161.5, 147.2, 139.6, 133.8 (q, *J*_{CF} = 31.7 Hz), 133.6, 131.4, 131.2, 123.2 (q, *J*_{CF} = 273.1 Hz), 122.9 (q, *J*_{CF} = 2.3 Hz), 122.7, 122.1, 119.3 (q, *J*_{CF} = 5.1 Hz), 74.1, 56.7, 56.2, 50.0, 42.3, 39.7, 39.5, 38.2, 38.0, 37.0, 36.6, 36.2, 35.8, 33.9, 31.9, 31.9, 28.2, 28.0, 27.8, 24.3, 24.3, 23.8, 22.8, 22.6, 21.0, 19.3, 18.7, 11.9; ¹⁹F NMR (376 MHz, CDCl₃) δ -61.6; HRMS (ESI-TOF) *m/z* [M + H]⁺ Calcd for C₄₁H₅₆ClF₃NO₂ 686.3952, found 686.3958.

6-Chloro-2-ferrocenyl-4-(trifluoromethyl)quinoline (3x). Title compound was prepared according to the general procedure from *o*-TFMK **1a** (111.8 mg, 0.5 mmol), ethynylferrocene (**2x**) (126.0 mg, 0.6 mmol, 1.2 equiv), IPr^{*}CuCl (10.1 mg, 0.00005 mmol, 2 mol %), TMG (1.25 μ L, 0.00005 mmol, 2 mol %), DME (100 μ L) and water (2 mL). The reaction mixture was heated at 100 $^{\circ}$ C for 16 h. Then reaction mixture was extracted with EtOAc (3 \times 10 mL), and the combined organic phases were washed with brine (1 \times 20 mL), dried over MgSO₄ and evaporated. The residue was chromatographed on silica (5% Et₂O/hexanes) to give a red solid (138.2 mg, 67%). mp 183.2–184.6 (CHCl₃, by slow evaporation); IR (KBr) 3103, 3068, 1908, 1792, 1612, 1550, 1494 cm⁻¹; ¹H NMR (400 MHz, CDCl₃) δ 8.04 (d, *J* = 9.0 Hz, 1H), 8.03–8.01 (m, 1H), 7.78 (s, 1H), 7.68 (dd, *J* = 9.0, 2.2 Hz, 1H), 5.08 (t, *J* = 2.0 Hz, 2H), 4.55 (t, *J* = 2.0 Hz, 2H), 4.09 (s, 5H); ¹³C NMR (100 MHz, CDCl₃) δ 159.8, 147.6, 133.0 (q, *J*_{CF} = 32.0 Hz), 132.7, 131.3, 131.1, 123.3 (q, *J*_{CF} = 273.0 Hz), 123.1 (q, *J*_{CF} = 2.3 Hz), 121.7, 117.0 (q, *J*_{CF} = 5.3 Hz), 82.3, 71.2, 69.8, 68.1; ¹⁹F NMR (376 MHz, CDCl₃) δ -61.8; HRMS (ESI-TOF) *m/z* [M + H]⁺ Calcd for C₂₀H₁₄ClF₃NFe 416.0116, found 416.0100.

(3S,4R)-3-[(1R)-1-[[tert-butyl(dimethyl)silyloxy]ethyl]-4-[[6-chloro-4-(trifluoromethyl)quinolin-2-yl]methyl]azetidino-2-one (3y). Title compound was prepared according to the general procedure from *o*-TFMK **1a** (111.8 mg, 0.5 mmol), (3S,4R)-3-[(1R)-[[tert-butyl(dimethyl)silyloxy]ethyl]-4-prop-2-yn-1-yl]azetidino-2-one (**2y**) (160.5 mg, 0.6 mmol, 1.1 equiv), IPr^{*}CuCl (10.1 mg, 0.00005 mmol, 2 mol %), TMG (1.25 μ L, 0.00005 mmol, 2 mol %), DME (100 μ L) and water (2 mL). The reaction mixture was heated at 100 $^{\circ}$ C for 16 h. Then reaction mixture was extracted with EtOAc (3 \times 3 mL), and the combined organic phases were washed with brine (1 \times 20 mL), dried over MgSO₄ and evaporated. The residue was chromatographed on silica (20% EtOAc/toluene) to give a white solid (123.1 mg, 52%). mp 129.4–130.3 $^{\circ}$ C (*n*-heptane); [a]_D²⁵ = 41.3 (c = 1.01, CHCl₃); IR (film) 3244, 2954, 2930, 2857, 1756, 1612 cm⁻¹; ¹H NMR (400 MHz, CDCl₃) δ 8.11–8.04 (m, 1H) overlapping 8.06 (d, *J* = 9.0 Hz, 1H), 7.75 (dd, *J* = 9.0, 2.2 Hz, 1H), 7.58 (s, 1H), 6.17 (br s, 1H), 4.27–4.18 (m, 2H), 3.41 (dd, *J* = 15.1, 4.4 Hz, 1H), 3.29 (dd, *J* = 15.1, 9.0 Hz, 1H), 3.03–2.97 (m, 1H), 1.15 (d, *J* = 6.2 Hz, 3H), 0.87 (s, 9H), 0.07 (s, 6H); ¹³C NMR (100 MHz, CDCl₃) δ 169.0, 158.7, 147.2, 134.2 (q, *J*_{CF} = 31.9 Hz), 134.1, 131.5, 123.0 (q, *J*_{CF} = 273.2 Hz), 123.0 (q, *J*_{CF} = 2.3 Hz), 122.2, 119.4 (q, *J*_{CF} = 5.1 Hz), 65.6, 64.4, 49.6, 43.5, 25.7, 22.5, 17.9, -4.3, -5.0; ¹⁹F NMR (376 MHz, CDCl₃) δ -61.7; HRMS (ESI-TOF) *m/z* [M + H]⁺ Calcd for C₂₂H₂₉ClF₃N₂O₂Si 473.1639, found 473.1638.

17-[6-Chloro-4-(trifluoromethyl)quinolin-2-yl]-3-methoxyestra-1-(10),2,4,16-tetraene (3z). Title compound was prepared according to the general procedure from *o*-TFMK **1a** (72.1 mg, 0.322 mmol, 1.2 equiv), 17-ethynyl-3-methoxyestra-1(10),2,4,16-tetraene (**2z**) (78.6 mg, 0.269 mmol), IPr^{*}CuCl (5.4 mg, 5.38 \times 10⁻⁶ mmol, 2 mol %),

TMG (0.67 μ L, 0.619 mg, 5.38 \times 10⁻⁶ mmol, 2 mol %), DME (100 μ L) and water (1.1 mL). The reaction mixture was heated at 100 $^{\circ}$ C for 48 h. Then reaction mixture was extracted with EtOAc (3 \times 10 mL), and the combined organic phases were washed with brine (1 \times 20 mL), dried over MgSO₄ and evaporated. The residue was chromatographed on silica (5% MTBE/hexanes, the unreacted *o*-TFMK was separated) to give a mixture of starting alkyne and quinoline derivative **3z**. This mixture was further separated by reversed-phase column chromatography (MeOH) to give **3z** as a white solid (86.9 mg, 62%). mp 96.6–97.7 (crystals were obtained by slow evaporation of DCM solution); [a]_D²⁵ = 49.9 (c = 0.72, CHCl₃); Purity based on HPLC: 99% (major peak 21.0 min, YMC-Pack Pro C18 column, 250 mm \times 4.6 mm, 5 μ m, UV detector 254 nm, MeOH; 1.0 mL/min); IR (KBr) 2923, 2851, 1610, 1550 cm⁻¹; ¹H NMR (400 MHz, CDCl₃) δ 8.08 (d, *J* = 9.0 Hz, 1H), 8.05–8.02 (m, 1H), 7.91 (s, 1H), 7.69 (dd, *J* = 9.0, 2.2 Hz, 1H), 7.25 (d, *J* = 9.0 Hz, 1H), 6.75 (dd, *J* = 8.5, 2.7 Hz, 1H), 6.69–6.64 (m, 2H), 3.80 (s, 3H), 3.04–2.86 (m, 3H), 2.47 (ddd, *J* = 16.4, 6.3, 3.4 Hz, 1H), 2.45–2.29 (m, 2H), 2.25 (ddd, *J* = 16.4, 11.5, 1.2 Hz, 1H), 2.04–1.95 (m, 1H), 1.91–1.40 (m, 5H), 1.23 (s, 3H); ¹³C NMR (100 MHz, CDCl₃) δ 157.5, 155.1, 154.2, 147.1, 137.9, 135.3, 133.3, 133.0 (q, *J*_{CF} = 31.5 Hz), 132.9, 132.0, 130.9, 126.1, 123.3 (q, *J*_{CF} = 273.0 Hz), 122.9 (q, *J*_{CF} = 2.3 Hz), 121.8, 117.5 (q, *J*_{CF} = 5.2 Hz), 113.9, 111.5, 56.4, 55.2, 47.9, 44.3, 37.2, 35.4, 32.0, 29.7, 27.8, 26.7, 16.2; ¹⁹F NMR (376 MHz, CDCl₃) δ -61.8; HRMS (ESI-TOF) *m/z* [M + H]⁺ Calcd for C₂₉H₂₈ClF₃NO 498.1812, found 498.1816.

2-Cyclopropyl-6-methoxy-4-(trifluoromethyl)quinoline (5a). Title compound was prepared according to the general procedure from 1-(2-amino-5-methoxyphenyl)-2,2,2-trifluoroethanone (**1b**) (109.6 mg, 0.5 mmol), cyclopropylacetylene (**2a**) (51.0 μ L, 0.6 mmol, 1.2 equiv), IPr^{*}CuCl (10.1 mg, 0.00005 mmol, 2 mol %), TMG (1.25 μ L, 0.00005 mmol, 2 mol %), DME (100 μ L) and water (2 mL). Reaction mixture was heated at 120 $^{\circ}$ C for 16 h. Then reaction mixture was extracted with EtOAc (3 \times 10 mL), and the combined organic phases were washed with brine (1 \times 20 mL), dried over MgSO₄ and evaporated. The residue was chromatographed on silica (2% EtOAc/hexanes) to give a light-yellow oil (89.8 mg, 67%). The reaction conducted on 0.5 mmol scale with IPr^{*}OMeCuCl (10.4 mg, 0.00005 mmol, 2 mol %) afforded product in 82% yield (109.4 mg, 82%). ¹H NMR (400 MHz, CDCl₃) δ 7.93 (d, *J* = 9.2 Hz, 1H), 7.47 (s, 1H), 7.37 (dd, *J* = 9.2, 2.7 Hz, 1H), 7.32–7.27 (m, 1H), 3.93 (s, 3H), 2.27–2.18 (m, 1H), 1.22–1.06 (m, 4H); ¹³C NMR (100 MHz, CDCl₃) δ 160.0, 157.8, 145.1, 132.6 (q, *J*_{CF} = 30.9 Hz), 131.0, 127.2 (q, *J*_{CF} = 277.1 Hz), 122.5, 117.2 (q, *J*_{CF} = 5.3 Hz), 102.0 (q, *J*_{CF} = 2.3 Hz), 55.5, 17.8, 10.3; ¹⁹F NMR (376 MHz, CDCl₃) δ -62.3. ¹H NMR spectral data are in agreement with those reported.⁶⁴ ¹³C NMR spectra are described by the authors without C–F coupling constants and the accurate description is provided above. A copy of the spectra is included in the SI.

2-Cyclopropyl-4-(trifluoromethyl)benzo[h]quinoline (5b). Title compound was prepared according to the general procedure from 1-(1-aminonaphthalene-2-yl)-2,2,2-trifluoroethanone (**1c**) (119.6 mg, 0.5 mmol), cyclopropylacetylene (**2a**) (51.0 μ L, 0.6 mmol, 1.2 equiv), IPr^{*}CuCl (10.1 mg, 0.00005 mmol, 2 mol %), TMG (1.25 μ L, 0.00005 mmol, 2 mol %) and water (2 mL). Reaction mixture was heated at 120 $^{\circ}$ C for 48 h. Then reaction mixture was extracted with EtOAc (3 \times 10 mL), and the combined organic phases were washed with brine (1 \times 20 mL), dried over MgSO₄ and evaporated. The residue was chromatographed on silica (5% EtOAc/hexanes) to give a colorless oil (58.1 mg, 40%). IR (KBr) 3092, 3000, 1603, 1560 cm⁻¹; ¹H NMR (400 MHz, CDCl₃) δ 9.30–9.23 (m, 1H), 7.98–7.78 (m, 3H), 7.76–7.66 (m, 3H), 2.37–2.28 (m, 1H), 1.43–1.36 (m, 2H), 1.23–1.15 (m, 2H); ¹³C NMR (100 MHz, CDCl₃) δ 161.7, 147.2, 133.8 (q, *J*_{CF} = 31.0 Hz), 133.4, 131.1, 128.6, 127.9, 127.6, 127.1, 124.9, 123.8 (q, *J*_{CF} = 273.1 Hz), 120.8 (q, *J*_{CF} = 2.5 Hz), 119.5 (q, *J*_{CF} = 1.4 Hz), 117.3 (q, *J*_{CF} = 5.4 Hz), 18.1, 11.5; ¹⁹F NMR (376 MHz, CDCl₃) δ -60.9; HRMS (ESI-TOF) *m/z* [M + H]⁺ Calcd for C₁₇H₁₃F₃N 288.1000, found 288.0992.

2-Cyclopropyl-6-fluoro-4-(trifluoromethyl)quinoline (5c). Title compound was prepared according to the general procedure from 1-

(2-amino-5-fluorophenyl)-2,2,2-trifluoroethanone (**1d**) (103.4 mg, 0.5 mmol), cyclopropylacetylene (**2a**) (51.0 μ L, 0.6 mmol, 1.2 equiv), IPr*CuCl (10.1 mg, 0.00005 mmol, 2 mol %), TMG (1.25 μ L, 0.00005 mmol, 2 mol %), DME (100 μ L) and water (2 mL). Reaction mixture was heated at 100 °C for 16 h. Then reaction mixture was extracted with EtOAc (3 \times 10 mL), and the combined organic phases were washed with brine (1 \times 20 mL), dried over MgSO₄ and evaporated. The residue was chromatographed on silica (2% EtOAc/hexanes) to give a colorless oil (97.5 mg, 76%). IR (KBr) 3094, 3013, 1931, 1627, 1566, 1514 cm⁻¹; ¹H NMR (400 MHz, CDCl₃) δ 8.02 (dd, J = 9.2, 5.6 Hz, 1H), 7.71–7.62 (m, 1H), 7.54 (br s, 1H), 7.52–7.44 (m, 1H), 2.30–2.19 (m, 1H), 1.28–1.04 (m, 4H); ¹³C NMR (100 MHz, CDCl₃) δ 162.2 (d, J_{CF} = 2.8 Hz), 160.4 (d, J_{CF} = 247.0 Hz), 146.1, 133.6 (dq, J_{CF} = 31.5, 5.6 Hz), 132.0 (d, J_{CF} = 9.2 Hz), 123.4 (q, J_{CF} = 272.8 Hz), 121.9 (d, J_{CF} = 9.4 Hz), 120.1 (d, J_{CF} = 25.4 Hz), 118.0 (q, J_{CF} = 5.2 Hz), 107.9 (dq, J_{CF} = 24.3, 2.2 Hz), 18.0, 10.8; ¹⁹F NMR (376 MHz, CDCl₃) δ -62.2, -111.9; HRMS (ESI-TOF) m/z [M + H]⁺ Calcd for C₁₃H₁₀F₄N 256.0749, found 256.0750.

2-Cyclopropyl-4-(trifluoromethyl)quinoline (5d). Title compound was prepared according to the general procedure from 1-(2-Aminophenyl)-2,2,2-trifluoroethanone (**1e**) (94.6 mg, 0.5 mmol), cyclopropylacetylene (**2a**) (51.0 μ L, 0.6 mmol, 1.2 equiv), IPr*CuCl (10.1 mg, 0.00005 mmol, 2 mol %), TMG (1.25 μ L, 0.00005 mmol, 2 mol %), DME (100 μ L) and water (2 mL). Reaction mixture was heated at 120 °C for 16 h. Then reaction mixture was extracted with EtOAc (3 \times 10 mL), and the combined organic phases were washed with brine (1 \times 20 mL), dried over MgSO₄ and evaporated. The residue was chromatographed on silica (2% EtOAc/hexanes) to give a colorless oil (89.0 mg, 75%). ¹H NMR (400 MHz, CDCl₃) δ 8.10–8.01 (m, 2H), 7.75–7.68 (m, 1H), 7.57–7.50 (m, 2H), 2.32–2.25 (m, 1H), 1.28–1.10 (m, 4H); ¹⁹F NMR (376 MHz, CDCl₃) δ -61.6. Spectral data are in agreement with those reported.²¹

2-Cyclopropyl-N,N-dimethyl-4-(trifluoromethyl)quinolin-6-amine (5f). Title compound was prepared according to the general procedure from 1-[2-Amino-5-(dimethylamino)phenyl]-2,2,2-trifluoroethanone (**1g**) (116.1 mg, 0.5 mmol), cyclopropylacetylene (**2a**) (51.0 μ L, 0.6 mmol, 1.2 equiv), IPr*CuCl (10.1 mg, 0.00005 mmol, 2 mol %), TMG (1.25 μ L, 0.00005 mmol, 2 mol %), DME (100 μ L) and water (2 mL). Reaction mixture was heated at 100 °C for 16 h. Then reaction mixture was extracted with EtOAc (4 \times 2 mL), and the combined organic phases were washed with brine (1 \times 20 mL), dried over Na₂SO₄ and evaporated. The residue was chromatographed on silica (10–30% EtOAc/hexanes) to give a yellow solid (103.6 mg, 74%). mp 75.0–75.4 (*n*-pentane); IR (KBr) 2923, 2852, 1620, 1609, 1508 cm⁻¹; ¹H NMR (400 MHz, CDCl₃) δ 7.90 (d, J = 9.4 Hz, 1H), 7.37 (s, 1H), 7.39–7.32 (dd, J = 9.4, 2.8 Hz, 1H), 7.02–6.97 (m, 1H), 3.08 (s, 6H), 2.25–2.15 (m, 1H), 1.17–1.09 (m, 2H), 1.09–1.02 (m, 2H); ¹³C NMR (100 MHz, CDCl₃) δ 157.6, 148.5, 143.0, 131.5 (q, J_{CF} = 30.5 Hz), 130.1, 124.1 (q, J_{CF} = 272.5 Hz), 123.0, 119.5, 116.9 (q, J_{CF} = 5.4 Hz), 101.2 (q, J_{CF} = 2.2 Hz), 40.5, 17.7, 9.7; ¹⁹F NMR (376 MHz, CDCl₃) δ -62.8; HRMS (ESI-TOF) m/z [M + H]⁺ Calcd for C₁₅H₁₆F₃N₂ 281.1266, found 281.1268.

2-Cyclopropyl-6-methyl-4-(trifluoromethyl)quinolone (5g). Title compound was prepared according to the general procedure from 1-(2-amino-5-methylphenyl)-2,2,2-trifluoroethanone (**1h**) (101.6 mg, 0.5 mmol), cyclopropylacetylene (**2a**) (51.0 μ L, 0.6 mmol, 1.2 equiv), IPr*CuCl (10.1 mg, 0.00005 mmol, 2 mol %), TMG (1.25 μ L, 0.00005 mmol, 2 mol %), DME (100 μ L) and water (2 mL). Reaction mixture was heated at 120 °C for 16 h. Then reaction mixture was extracted with EtOAc (3 \times 10 mL), and combined organic phases were washed with brine (1 \times 20 mL), dried over MgSO₄ and evaporated. The residue was chromatographed on silica (2% EtOAc/hexanes) to give a colorless oil which solidified upon standing (102.3 mg, 81%). mp 64.3–64.8 (*n*-heptane, -78 °C); IR (KBr) 3092, 3006, 2922, 2867, 1611, 1561, 1506 cm⁻¹; ¹H NMR (400 MHz, CDCl₃) δ 7.93 (br d, J = 8.6 Hz, 1H), 7.81 (br s, 1H), 7.55 (dd, J = 8.6, 1.6 Hz, 1H), 7.47 (s, 1H), 2.55 (s, 3H), 2.30–2.20 (m, 1H), 1.26–1.07 (m, 4H); ¹³C NMR (100 MHz, CDCl₃) δ 161.7, 147.5, 136.7, 133.3 (q, J_{CF} = 31.1 Hz), 132.1, 129.3, 123.7 (q, J_{CF} = 272.9 Hz), 122.7 (q, J_{CF} = 2.1 Hz), 121.4, 116.9 (q, J_{CF} = 5.3 Hz), 21.9, 18.0, 10.5; ¹⁹F NMR (376

MHz, CDCl₃) δ -61.6; HRMS (ESI-TOF) m/z [M + H]⁺ Calcd for C₁₄H₁₃F₃N 252.1000, found 252.1001.

2-Cyclopropyl-6-((1R,2S,5R)-5-methyl-2-(propan-2-yl)cyclohexyloxy)-4-(trifluoromethyl)quinoline (5h). Title compound was prepared according to the general procedure from 1-(2-amino-5-((1R,2S,5R)-5-methyl-2-(propan-2-yl)cyclohexyloxy)phenyl)-2,2,2-trifluoroethanone (**1i**) (171.7 mg, 0.5 mmol), cyclopropylacetylene (**2a**) (51.0 μ L, 0.6 mmol, 1.2 equiv), IPr*CuCl (10.1 mg, 0.00005 mmol, 2 mol %), TMG (1.25 μ L, 0.00005 mmol, 2 mol %), DME (100 μ L) and water (2 mL). Reaction mixture was heated at 100 °C for 16 h. Then reaction mixture was extracted with EtOAc (4 \times 2 mL), and the combined organic phases were washed with brine (1 \times 20 mL), dried over Na₂SO₄ and evaporated. The residue was chromatographed on silica (30–50% EtOAc/hexanes) to give a yellow oil (109.8 mg, 56%). IR (KBr) 2956, 2927, 2871, 1620, 1502 cm⁻¹; ¹H NMR (400 MHz, CDCl₃) δ 7.93 (d, J = 9.1 Hz, 1H), 7.45 (s, 1H), 7.40–7.32 (m, 2H), 4.18 (dd, J = 10.5, 10.5, 4.1 Hz, 1H), 2.28–2.15 (m, 3H), 1.81–1.69 (m, 2H), 1.65–1.46 (m, 2H), 1.19–1.13 (m, 3H), 1.13–1.05 (m, 3H), 1.00–0.97 (m, 1H), 0.95 (d, J = 7.0 Hz, 3H), 0.94 (d, J = 6.6 Hz, 3H), 0.79 (d, J = 7.0 Hz, 3H); ¹³C NMR (100 MHz, CDCl₃) δ 159.8, 156.6, 144.9, 132.5 (q, J_{CF} = 30.8 Hz), 131.0, 123.8 (q, J_{CF} = 272.9 Hz), 123.1, 122.6, 117.1 (q, J_{CF} = 5.3 Hz), 104.8 (q, J_{CF} = 2.2 Hz), 78.2, 48.1, 40.1, 34.5, 31.4, 26.2, 23.7, 22.1, 20.7, 17.8, 16.6, 10.2, 10.2; ¹⁹F NMR (376 MHz, CDCl₃) δ -62.3; HRMS (ESI-TOF) [M + H]⁺ Calcd for C₂₃H₂₉F₃NO 392.2201, found 392.2198.

2-Cyclopropyl-4-(trifluoromethyl)-1,8-naphthyridine (5i). Title compound was prepared according to the general procedure 1-(2-aminopyridin-3-yl)-2,2,2-trifluoroethanone (**6a**) (95.0 mg, 0.5 mmol), cyclopropylacetylene (**2a**) (51.0 μ L, 0.6 mmol, 1.2 equiv), IPr*^{OMe}CuCl (10.4 mg, 0.00005 mmol, 2 mol %), TMG (1.25 μ L, 0.00005 mmol, 2 mol %), DME (100 μ L) and water (2 mL). Reaction mixture was heated at 120 °C for 16 h. Then reaction mixture was extracted with EtOAc (4 \times 2 mL), and the combined organic phases were washed with brine (1 \times 20 mL), dried over Na₂SO₄ and evaporated. The residue was chromatographed on silica (30% EtOAc/hexanes) to give an orange solid (93.7 mg, 79%). mp 71.3–71.8 °C (*n*-pentane); IR (KBr) 3078, 3004, 1622, 1599, 1507 cm⁻¹; ¹H NMR (400 MHz, CDCl₃) δ 9.10 (dd, J = 2.4 Hz, J = 1.7 Hz, 1H), 8.45–8.38 (m, 1H), 7.68 (s, 1H), 7.49 (dd, J = 8.4, 4.2 Hz, 1H), 2.34–2.25 (m, 1H), 1.48–1.42 (m, 2H), 1.24–1.17 (m, 2H); ¹³C NMR (100 MHz, CDCl₃) δ 167.7, 156.5, 153.9, 134.9 (q, J_{CF} = 31.8 Hz), 133.3 (q, J_{CF} = 2.0 Hz), 123.0 (q, J_{CF} = 273.4 Hz), 121.9, 119.0 (q, J_{CF} = 5.0 Hz), 116.2, 18.6, 12.5; ¹⁹F NMR (376 MHz, CDCl₃) δ -61.0; HRMS (ESI-TOF) m/z [M + Na]⁺ Calcd for C₁₂H₉F₃N₂Na 261.0616, found 261.0614.

6-Chloro-2-cyclopropyl-4-(trifluoromethyl)-1,8-naphthyridine (5k). Title compound was prepared according to the general procedure from 1-(2-amino-5-chloropyridin-3-yl)-2,2,2-trifluoroethanone (**6c**) (101.5 mg, 0.5 mmol), cyclopropylacetylene (**2a**) (51.0 μ L, 0.6 mmol, 1.2 equiv), IPr*CuCl (10.1 mg, 0.00005 mmol, 2 mol %), TMG (1.25 μ L, 0.00005 mmol, 2 mol %) and water (2 mL). Reaction mixture was heated at 100 °C for 16 h. Then reaction mixture was extracted with EtOAc (3 \times 10 mL), and the combined organic phases were washed with brine (1 \times 20 mL), dried over MgSO₄ and evaporated. The residue was chromatographed on silica (10% Et₂O/*n*-pentane) to give a colorless oil which solidified upon standing in the fridge (68.2 mg, 50%). mp 93.0–94.4 °C (crystals were obtained by slow evaporation of DCM solution; attempts to crystallize quinoline **5k** from *n*-heptane, *n*-pentane, or its mixture with EtOH, Et₂O has failed); IR (film) 3088, 3069, 3011, 1611, 1478 cm⁻¹; ¹H NMR (400 MHz, CDCl₃) δ 9.00 (d, J = 2.5 Hz, 1H), 8.37–8.32 (m, 1H), 7.70 (s, 1H), 2.34–2.23 (m, 1H), 1.48–1.38 (m, 2H), 1.27–1.17 (m, 2H); ¹³C NMR (100 MHz, CDCl₃) δ 168.0, 154.5, 153.2, 134.2 (q, J_{CF} = 32.1 Hz), 131.6 (q, J_{CF} = 2.2 Hz), 129.5, 122.7 (q, J_{CF} = 273.2 Hz), 119.8 (q, J_{CF} = 5.0 Hz), 116.4, 18.7, 12.7; ¹⁹F NMR (376 MHz, CDCl₃) δ -61.2; HRMS (ESI-TOF) m/z [M + H]⁺ Calcd for C₁₂H₉F₃N₂Cl 273.0406, found 273.0407.

2-Cyclopropyl-4-(trifluoromethyl)-1,6-naphthyridine (5l). Title compound was prepared according to the general procedure from 1-(4-aminopyridin-3-yl)-2,2,2-trifluoroethanone (**6b**) (95.0 mg, 0.5

mmol), cyclopropylacetylene (**2a**) (51.0 μL , 0.6 mmol, 1.2 equiv), IPr^*CuCl (10.4 mg, 0.00005 mmol, 2 mol %), TMG (1.25 μL , 0.00005 mmol, 2 mol %), DME (100 μL) and water (2 mL). Reaction mixture was heated at 120 °C for 16 h. Then reaction mixture was extracted with EtOAc (4 \times 2 mL), and the combined organic phases were washed with brine (1 \times 20 mL), dried over Na_2SO_4 and evaporated. The residue was chromatographed on silica (1.5–3% acetone/DCM) to give an orange solid (49.2 mg, 41%). mp 118.2–118.9 °C (*n*-pentane); IR (KBr) 3015, 1613, 1599 cm^{-1} ; ^1H NMR (400 MHz, CDCl_3) δ 9.47 (s, 1H), 8.78 (d, J = 5.8 Hz, 1H), 7.83 (d, J = 5.8 Hz, 1H), 7.62 (s, 1H), 2.33–2.26 (m, 1H), 1.41–1.29 (m, 2H), 1.29–1.17 (m, 2H); ^{13}C NMR (100 MHz, CDCl_3) δ 168.6, 151.2, 148.9 (q, J_{CF} = 3.0 Hz), 147.6, 134.2 (q, J_{CF} = 32.9 Hz), 122.9 (q, J_{CF} = 273.3 Hz), 122.0, 118.8 (q, J_{CF} = 5.2 Hz), 117.0, 18.8, 12.4; ^{19}F NMR (376 MHz, CDCl_3) δ -60.7; HRMS (ESI-TOF) m/z [$\text{M} + \text{H}$] $^+$ Calcd for $\text{C}_{12}\text{H}_{10}\text{F}_3\text{N}_2$ 239.0796, found 239.0794.

6-Chloro-2-cyclopropyl-4-(heptafluoropropyl)quinolone (5m). Title compound was obtained according to the general procedure from ketone 1-(2-amino-5-chlorophenyl)-2,2,3,3,4,4,4-heptafluorobutan-1-ol (**1j**) (161.8 mg, 0.5 mmol), TMG (1.25 μL , 0.01 mmol, 2 mol %), cyclopropylacetylene **2a** (55.0 μL , 0.6 mmol, 1.2 equiv), IPr^*CuCl (10.2 mg, 0.01 mmol, 2 mol %), water (2 mL) and DME (0.1 mL). The reaction mixture was heated at 120 °C for 16 h. The crude product was chromatographed on silica (5% $\text{Et}_2\text{O}/n$ -pentane) to give quinoline **5m** as a colorless oil (54.3 mg, 29%, 92% based on recovered starting ketone) and unreacted substrate (72.3 mg). Additional experiments were conducted with 2 mol % of IPr^*CuCl to afford product **5m** with 51% (94.6 mg, after 16 h at 120 °C) and 56% (103.6 mg, after 48 h at 120 °C) and 5 mol % of IPr^*CuCl (126.3 mg of **5m**, 68%). IR (film) 3011, 1604, 1557, 1496 cm^{-1} ; ^1H NMR (400 MHz, CDCl_3) δ 8.07–8.01 (m, 1H), 7.96 (d, J = 9.0 Hz, 1H), 7.65 (dd, J = 9.0, 2.2 Hz, 1H), 7.50 (s, 1H), 2.30–2.20 (m, 1H), 1.28–1.11 (m, 4H); ^{13}C NMR (100 MHz, CDCl_3) δ 163.0, 147.6, 132.8, 132.0 (t, J_{CF} = 22.8 Hz), 131.4, 130.8, 123.3–123.6 (m), 123.0, 121.0 (t, J_{CF} = 8.6 Hz), 18.0, 11.2. Signals in the region of 120–102 ppm has been omitted in description of spectra for clarity due to complicated multiplicity; ^{19}F NMR (376 MHz, CDCl_3) δ -77.8 (t, J = 10.2 Hz), -107.8 to -108.0 (m), -124.7 to -124.8 (m); HRMS (ESI-TOF) m/z [$\text{M} + \text{H}$] $^+$ Calcd for $\text{C}_{15}\text{H}_{10}\text{ClF}_7\text{N}$ 372.0390, found 372.0380.

6-Chloro-2-cyclopropyl-4-(difluoromethyl)quinolone (5n). Title compound was prepared according to the general procedure from 1-(2-amino-5-chlorophenyl)-2,2-difluoroethanone (**1k**) (102.8 mg, 0.5 mmol), cyclopropylacetylene (**2a**) (51.0 μL , 0.6 mmol, 1.2 equiv), IPr^*CuCl (10.1 mg, 0.00005 mmol, 2 mol %), TMG (1.25 μL , 0.00005 mmol, 2 mol %), water (2 mL) and DME (0.1 mL). Reaction mixture was heated at 100 °C for 16 h. Then reaction mixture was extracted with EtOAc (3 \times 10 mL), and combined organic phases were washed with brine (1 \times 20 mL), dried over MgSO_4 and evaporated. The residue was chromatographed on silica (5% EtOAc/hexanes) to give a colorless oil (68.7 mg, 54%). Additional experiment was conducted on the same scale at 100 °C for 48 h to give a quinoline **5n** with 73% (92.6 mg). mp 63.7–64.1; IR (film) 3090, 3013, 2972, 1743, 1613 1557 cm^{-1} ; ^1H NMR (400 MHz, CDCl_3) δ 8.00–7.91 (m, 2H), 7.63 (dd, J = 9.0, 2.2 Hz, 1H), 7.39 (br s, 1H), 7.02 (t, J_{HF} = 54.5 Hz, 1H), 2.29–2.19 (m, 1H), 1.27–1.08 (m, 4H); ^{13}C NMR (100 MHz, CDCl_3) δ 163.6, 147.0, 136.7 (t, J_{CF} = 21.6 Hz), 132.1, 131.1, 130.6, 123.1 (t, J_{CF} = 2.8 Hz), 122.3, 117.9 (t, J_{CF} = 7.7 Hz), 113.4 (t, J_{CF} = 239.2 Hz), 18.1, 10.7; ^{19}F NMR (376 MHz, CDCl_3) δ -114.9; HRMS (EI) m/z [M^+] Calcd for $\text{C}_{13}\text{H}_{10}\text{F}_2\text{NCl}$ 253.0470, found 253.0491.

3-[6-Chloro-4-(difluoromethyl)quinolin-2-yl]propan-1-ol (5o). Title compound was prepared according to the general procedure from 1-(2-Amino-5-chlorophenyl)-2,2-difluoroethanone (**1k**) (102.8 mg, 0.5 mmol), pent-4-yn-1-ol (**2l**) (56.0 μL , 0.6 mmol, 1.2 equiv), IPr^*CuCl (10.1 mg, 0.00005 mmol, 2 mol %), TMG (1.25 μL , 0.00005 mmol, 2 mol %), water (2 mL) and DME (0.1 mL). Reaction mixture was heated at 100 °C for 16 h. Then reaction mixture was extracted with EtOAc (3 \times 10 mL), and combined organic phases were washed with brine (1 \times 20 mL), dried over MgSO_4 and

evaporated. The residue was chromatographed on silica (50–75% EtOAc/hexanes) to give a light-yellow oil which solidified upon standing (96.4 mg, 71%). The experiment was conducted on the same scale at 100 °C for 48 h, affording product **5o** with 77% (104.1 mg) yield. mp 75.5–76.8 (*n*-pentane); IR (KBr) 3252, 2950, 2925, 2858, 1620, 1567 cm^{-1} ; ^1H NMR (400 MHz, CDCl_3) δ 8.06–7.99 (m, 2H), 7.70 (dd, J = 9.0, 2.3 Hz, 1H), 7.52 (br s, 1H), 7.05 (t, J_{HF} = 54.4 Hz, 1H), 3.77 (t, J = 7.7 Hz, 2H), 3.23 (br s, 1H, OH) overlapping 3.19 (t, J = 7.0 Hz, 2H), 2.18–2.06 (m, 2H); ^{13}C NMR (100 MHz, CDCl_3) δ 162.2, 146.4, 137.6 (t, J_{CF} = 21.8 Hz), 133.2, 131.0, 131.0, 123.2 (t, J_{CF} = 2.7 Hz), 122.4 (t, J_{CF} = 1.4 Hz), 119.6 (t, J_{CF} = 7.6 Hz), 113.2 (t, J_{CF} = 239.5 Hz), 62.3, 36.0, 31.1; ^{19}F NMR (376 MHz, CDCl_3) δ -115.0; HRMS (ESI-TOF) m/z [$\text{M} + \text{H}$] $^+$ Calcd for $\text{C}_{13}\text{H}_{13}\text{F}_2\text{NOCl}$ 272.0654, found 272.0646.

3(β)-Cholest-5-en-3-yl [4-(6-Chloro-4-(difluoromethyl)quinolin-2-yl)butanoate (5p). Title compound was prepared according to the general procedure from 1-(2-amino-5-chlorophenyl)-2,2-difluoroethanone (**1k**) (102.8 mg, 0.5 mmol), (β)-cholest-4-en-3-yl hex-5-ynoate (**2r**) (280.1 mg, 0.58 mmol, 1.2 equiv), IPr^*CuCl (10.1 mg, 0.00005 mmol, 2 mol %), TMG (1.25 μL , 0.00005 mmol, 2 mol %), water (2 mL) and DME (0.1 mL). Reaction mixture was heated at 100 °C for 16 h. Then reaction mixture was extracted with EtOAc (3 \times 10 mL), and combined organic phases were washed with brine (1 \times 20 mL), dried over MgSO_4 and evaporated. The residue was chromatographed on silica (10% MTBE/hexanes). Thus, obtained mixture of steroidal alkyne and product **5p** was subjected to chromatography on RP-18 silica (MeOH) to give a white solid (173.9 mg, 52%). [a] $_{\text{D}}^{25}$ = -13.1 (c = 1.32, MeOH/ CHCl_3 1/1); mp 110.5–111.7 (attempts to crystallize quinoline **5p** failed; compound does not dissolved in common organic solvents, DCM, EtOH, MeOH, DMSO, DMF, hexanes, MeCN, MTBE, Et $_2$ O; slightly soluble in CHCl_3 , ca. 2 mg/5 mL); IR (film) 3439, 2947, 2868, 1729, 1611 cm^{-1} ; ^1H NMR (400 MHz, CDCl_3) δ 8.05 (d, J = 9.1 Hz, 1H), 8.04–8.01 (m, 1H), 7.69 (dd, J = 9.1, 2.2 Hz, 1H), 7.49 (s, 1H), 7.05 (t, J = 54.4 Hz, 1H), 5.39–5.34 (m, 1H), 4.69–4.55 (m, 1H), 3.05 (t, J = 7.5 Hz, 2H), 2.41 (t, J = 7.4 Hz, 2H), 2.34–2.26 (m, 2H), 2.23–2.13 (m, 2H), 2.05–1.92 (m, 5H), 1.90–1.77 (m, 5H), 1.62–0.86 (m, 16H) overlapping 1.01 (s, 3H), 0.92 (d, J = 6.5 Hz, 3H), 0.87 (d, J = 6.6 Hz, 3H), 0.86 (d, J = 6.6 Hz, 3H), 0.68 (s, 3H); ^{13}C NMR (100 MHz, CDCl_3) δ 172.6, 161.8, 146.9, 139.6, 137.3 (t, J_{CF} = 22.0 Hz), 131.4, 130.8, 123.3 (t, J_{CF} = 2.5 Hz), 122.7, 122.4, 119.4 (t, J_{CF} = 7.6 Hz), 113.3 (t, J_{CF} = 239.4 Hz), 74.1, 56.7, 56.2, 50.1, 42.3, 39.8, 39.5, 38.2, 38.1, 37.0, 36.6, 36.2, 35.8, 34.0, 31.9, 31.9, 29.7, 28.2, 28.0, 27.8, 24.5, 24.3, 23.8, 22.8, 22.6, 21.0, 19.3, 18.7, 11.7; ^{19}F NMR (376 MHz, CDCl_3) δ -114.8; HRMS (ESI-TOF) m/z [$\text{M} + \text{H}$] $^+$ Calcd for $\text{C}_{41}\text{H}_{57}\text{F}_2\text{NO}_2\text{Cl}$ 668.4046, found 668.4043.

Synthesis of Dibenzo[b,f][1,5]diazocines. 2,8-Dichloro-6,12-bis(trifluoromethyl)-5,6,11,12-tetrahydro-6,12-epoxydibenzo[b,f][1,5]diazocine (4a). 1-(2-Amino-5-chlorophenyl)-2,2,2-trifluoroethanone (**1a**) (223.6 mg, 1.0 mmol), TMG (25.1 μL , 0.2 mmol, 20 mol %) and water (2 mL) were placed in a screw-cap 4 mL vial and heated at 100 °C (temp. of oil bath) for 16 h. Then reaction mixture was extracted with EtOAc (3 \times 10 mL). The combined organic extracts were dried over MgSO_4 and evaporated. The residue was chromatographed on silica (5% EtOAc/hexanes). Compound **4a** was isolated as a yellow oil (141.2 mg, 66%) which spontaneously solidified upon standing in the fridge. mp 217–220 °C (EtOAc; by slow evaporation); IR (film) 3379, 3350, 1610 cm^{-1} ; ^1H NMR (600 MHz, CDCl_3) δ 7.43 (s, 2H), 7.22 (dd, J = 8.6, 2.3 Hz, 2H), 6.81 (d, J = 8.6 Hz, 2H), 4.90 (br s, NH, 2H); ^{13}C NMR (150 MHz, CDCl_3) δ 138.4, 130.9, 127.6, 125.6 (q, $J_{\text{C-F}}$ = 32.0 Hz), 122.4 (q, $J_{\text{C-F}}$ = 282.5 Hz), 121.4, 120.8, 82.9 (q, J = 32.3 Hz); ^{19}F NMR (470 MHz, CDCl_3) δ -79.1. HRMS (ESI-TOF) m/z [$\text{M} - \text{H}$] $^-$ Calcd for $\text{C}_{16}\text{H}_7\text{Cl}_2\text{F}_6\text{N}_2\text{O}$ 426.9840, found 426.9845. Spectral data are in agreement with those reported.³¹

2,8-Fluoro-6,12-bis(trifluoromethyl)-5,6,11,12-tetrahydro-6,12-epoxydibenzo[b,f][1,5]diazocine (4b). 1-(2-Amino-5-fluorophenyl)-2,2,2-trifluoroethanone (**1d**) (207.1 mg, 1.0 mmol), Et_3N (28 μL , 0.2 mmol), TMG (25.1 μL , 0.2 mmol, 20 mol %) and water (2 mL) were placed in a screw-cap 4 mL vial and heated at 100 °C (temp. of oil bath) for 16 h. Then reaction mixture was diluted with water (10 mL) and extracted with EtOAc (3 \times 10 mL). The combined organic

extracts were dried over MgSO_4 and evaporated. The residue was chromatographed on silica (5% EtOAc/hexanes). Compound **4b** was isolated as a yellow oil (154.7 mg, 78%) which spontaneously solidified upon standing in the fridge. mp 169.1–169.5 °C (DCM; by slow evaporation); IR (film) 3426, 3370, 3328, 1891, 1725, 1499 cm^{-1} ; ^1H NMR (400 MHz, CDCl_3) δ 7.23–7.17 (m, 2H), (ddd, $J = 8.9, 7.9, 2.8$ Hz, 2H), 6.86 (dd, $J = 8.9, 4.9$ Hz, 2H), 4.77 (s, 2H); ^{13}C NMR (100 MHz, CDCl_3) δ 158.2 (d, $J_{\text{CF}} = 241.1$ Hz), 135.9 (d, $J_{\text{CF}} = 2.4$ Hz), 122.5 (q, $J_{\text{CF}} = 282.3$ Hz), 121.7 (d, $J_{\text{CF}} = 7.8$ Hz), 121.6 (d, $J_{\text{CF}} = 7.2$ Hz), 118.2 (d, $J_{\text{CF}} = 23.0$ Hz), 112.6 (dq, $J_{\text{CF}} = 24.5, 3.2$ Hz), 83.4 (dq, $J_{\text{CF}} = 32.0, 2.1$ Hz); ^{19}F NMR (376 MHz, CDCl_3) δ -79.3, -118.8; HRMS (ESI-TOF) m/z $[\text{M} - \text{H}]^-$ Calcd for $\text{C}_{16}\text{H}_7\text{F}_8\text{N}_2\text{O}$ 395.0431, found 395.0439.

Synthesis of Fluorinated Analogue of G Protein-Coupled Receptor Antagonist (GPR91). Ethyl 4-[4-(trifluoromethyl)-1,8-naphthyridin-2-yl]butanoate (**5j**). Title compound was prepared according to the general procedure 1-(2-aminopyridin-3-yl)-2,2,2-trifluoroethanone (**6a**) (1.33 g, 7.0 mmol), ethyl hex-5-ynoate (**7**) (1.18 g, 8.4 mmol, 1.2 equiv), $\text{IPr}^*\text{OMeCuCl}$ (145.6 mg, 0.14 mmol, 2 mol %), TMG (17.5 μL , 0.14 mmol, 2 mol %), water (28 mL) and DME (1.4 mL). Reaction mixture was heated at 120 °C for 20 h. Then reaction mixture was extracted with EtOAc (4 \times 20 mL), and combined organic phases were washed with brine (1 \times 20 mL), dried over Na_2SO_4 and evaporated. The residue was chromatographed on silica (30–50% EtOAc/hexanes) to give an orange oil (1.61 g, 74%). IR (film) 2981, 2938, 1732, 1621, 1601 1555, 1504 cm^{-1} ; ^1H NMR (400 MHz, CDCl_3) δ 9.20–9.10 (m, 1H), 8.44 (d, $J = 8.3$ Hz, 1H), 7.66 (s, 1H), 7.58–7.52 (dd, $J = 8.4, 4.2$ Hz, 1H), 4.10 (q, $J = 7.1$ Hz, 2H), 3.14 (t, $J = 7.4$ Hz, 2H), 2.43 (t, $J = 7.2$ Hz, 2H), 2.31–2.19 (m, 2H), 1.22 (t, $J = 7.2$ Hz, 3H); ^{13}C NMR (100 MHz, CDCl_3) δ 173.0, 165.2, 156.2, 154.1, 135.6 (q, $J_{\text{CF}} = 31.9$ Hz), 133.2 (q, $J_{\text{CF}} = 2.0$ Hz), 122.9 (q, $J_{\text{CF}} = 273.3$ Hz), 122.6, 119.5 (q, $J_{\text{CF}} = 4.9$ Hz), 116.4, 60.3, 38.2, 33.5, 23.9, 14.1; ^{19}F NMR (376 MHz, CDCl_3) δ -60.9; HRMS (ESI-TOF) m/z $[\text{M} + \text{Na}]^+$ Calcd for $\text{C}_{15}\text{H}_{15}\text{F}_3\text{N}_2\text{O}_2\text{Na}$ 335.0983, found 335.0976.

Methyl 4'-cyano-3,3'-difluorobiphenyl-2-carboxylate (11). To a solution of nitrile **8** (4.0 g, 20.0 mmol) in anhydrous DME (25 mL), cooled to -20 °C, commercially available solution of *i*-PrMgCl-LiCl (14.6 mL, 19.0 mmol, 1.3 M in THF) was added (the color of the reaction mixture changed from light-yellow to deep orange). After 15 min, a freshly prepared solution of $\text{CuCN}\cdot 2\text{LiCl}$ in THF (by mixing of CuCN , 1.62 g, 18.0 mmol and LiCl , 1.53 g, 36 mmol in THF, 25 mL) was added dropwise (the color of the reaction mixture changed from deep orange to green) and stirred for additional 15 min at -20 °C. In a separate Schlenk tube, a solution of iodoester **10** (1.82 g, 6.5 mmol) and $\text{Fe}(\text{acac})_3$ (230.0 mg, 0.65 mmol, 10 mol %) in anhydrous DME (15 mL) was prepared and slowly added to the organocopper compound **9**. The resulting mixture was stirred at 80 °C (temp. of oil bath) for 20 h. Then reaction mixture was quenched with a saturated aqueous solution of NH_4Cl (30 mL) and extracted with EtOAc (4 \times 50 mL). The combined organic extracts were washed with brine (1 \times 100 mL), dried over Na_2SO_4 and evaporated. The residue was chromatographed on silica (15–30% MTBE/hexanes) giving a yellow solid (1.45 g, 81%). ^1H NMR (400 MHz, CDCl_3) δ 7.72–7.65 (m, 1H), 7.58–7.50 (m, 1H), 7.30–7.14 (m, 4H), 3.76 (s, 3H); CAS registry number 1026635–99–3; no spectroscopic data are available for comparison.

[3,3'-Difluoro-2'-(methoxycarbonyl)biphenyl-4-yl]methanaminium chloride (12). To a solution of nitrile **11** (1.43 g, 5.23 mmol) in anhydrous MeOH (100 mL), a solution of HCl in MeOH (6.25 mL, 1.5 equiv, 1.25 M in MeOH) and 10% Pd/C (278 mg, 0.26 mmol, 5 mol %) were added. The flask was evacuated (water aspirator) and backfilled with hydrogen (3 times) and the reaction mixture was vigorously stirred at rt under atmosphere of hydrogen (balloon). After 16 h, argon was purged through the reaction mixture for 10 min and then it was filtered through a pad of Celite (washing with MeOH). Then, the solvent was evaporated and the residue was treated with MTBE (50 mL), heated to reflux for 15 min and filtered while hot. The obtained solid was washed with MTBE (2 \times 10 mL) and dried in vacuo to afford hydrochloride **12** as an off-white solid

(1.13 g, 69%). mp 210.1–210.5 °C; IR (KBr) 2970, 2951, 2909, 2875, 2707, 2627, 2021, 1741, 1627, 1609, 1568, 1508 cm^{-1} ; ^1H NMR (400 MHz, $\text{DMSO}-d_6$) δ 8.72 (br s, 3H), 7.79–7.58 (m, 2H), 7.48–7.16 (m, 4H), 4.09 (br s, 2H), 3.70 (s, 3H); ^{13}C NMR (100 MHz, $\text{DMSO}-d_6$) δ 165.1, 160.0 (d, $J_{\text{CF}} = 246.3$ Hz), 158.8 (d, $J_{\text{CF}} = 247.1$ Hz), 141.0 (dd, $J_{\text{CF}} = 8.0, 2.0$ Hz), 139.6, 132.4 (d, $J_{\text{CF}} = 9.1$ Hz), 131.6 (d, $J_{\text{CF}} = 3.7$ Hz), 125.9 (d, $J_{\text{CF}} = 2.8$ Hz), 124.1 (d, $J_{\text{CF}} = 3.0$ Hz), 121.0 (d, $J_{\text{CF}} = 32.5$ Hz), 120.8 (d, $J_{\text{CF}} = 35.1$ Hz), 115.5 (d, $J_{\text{CF}} = 21.2$ Hz), 114.9 (d, $J_{\text{CF}} = 22.7$ Hz), 52.7, 35.3 (d, $J_{\text{CF}} = 4.0$ Hz); ^{19}F NMR (376 MHz, $\text{DMSO}-d_6$) δ -115.7, -116.3; Anal. Calcd for $\text{C}_{15}\text{H}_{14}\text{ClF}_2\text{NO}_2\cdot 1/2\text{H}_2\text{O}$: C, 55.82; H, 4.68; N, 4.34 Found: C, 55.84; H, 4.74; N, 4.67; HRMS (ESI-TOF) m/z $[\text{M} - \text{Cl}]^+$ Calcd for $\text{C}_{15}\text{H}_{14}\text{F}_2\text{NO}_2$: 278.0993, found 278.0984.

Lithium 4-[4-(trifluoromethyl)-1,8-naphthyridin-2-yl]butanoate. To a solution of ester **5j** (1.0 g, 3.2 mmol) in a mixture of THF (50 mL) and water (2 mL), $\text{LiOH}\cdot\text{H}_2\text{O}$ (268.5 mg, 6.4 mmol, 2.0 equiv) was added at rt and stirred for 16 h. Then, the solvent was evaporated and the residue was dried in vacuo for 16 h to give a yellow solid (928.5 mg). The resulting lithium salt was used in the next step without further purification and can be stored for a long time without decomposition under argon atmosphere.

Methyl 3,3'-difluoro-4'-[[4-(4-(trifluoromethyl)-1,8-naphthyridin-2-yl]butanoyl)amino)methyl]biphenyl-2-carboxylate (13). To a solution of lithium 4-[4-(trifluoromethyl)-1,8-naphthyridin-2-yl]butanoate (863.0 mg, 2.97 mmol) in anhydrous DMF (60 mL), HOBt (683.3 mg, 4.46 mmol, 1.5 equiv) was added and stirred for 15 min (until all of the solid has dissolved). Then, amine hydrochloride **12** (977.4 mg, 3.12 mmol, 1.05 equiv) was added and stirred at rt. After 15 min, the reaction mixture was cooled to 0 °C and EDC-HCl (854.0 mg, 4.46 mmol, 1.5 equiv) was added in one portions (color of the reaction mixture changed from yellow to light-green). After additional 15 min. DIPEA (1.54 mL, 8.91 mmol, 3.0 equiv) was added, the cooling bath was removed and the resulting reaction mixture was stirred at rt for 16 h. The reaction mixture was cooled to 0 °C and water was slowly added (50 mL). The resulting mixture was diluted with EtOAc (30 mL), and the organic phase was separated, washed with water (2 \times 75 mL), brine (7 \times 50 mL), dried over Na_2SO_4 and the solvents were evaporated. The residue was chromatographed on silica (1–3% MeOH/DCM) to give an off-white gummy solid (1.013 g, 63%, after 2 steps). IR (film) 3291, 3060, 2952, 1736, 1657, 1555 cm^{-1} ; ^1H NMR (400 MHz, CDCl_3) δ 9.05 (br d, $J = 2.6$ Hz, 1H), 8.42 (d, $J = 8.3$ Hz, 1H), 7.68 (s, 1H), 7.53 (dd, $J = 8.4, 4.2$ Hz, 1H), 7.43–7.32 (m, 2H), 7.12–7.96 (m, 4H), 6.89–6.82 (m, 1H), 4.50 (d, $J = 5.7$ Hz, 2H), 3.66 (s, 3H), 3.14 (t, $J = 7.3$ Hz, 2H), 2.42 (t, $J = 7.1$ Hz, 2H), 2.32–2.21 (m, 2H); ^{13}C NMR (100 MHz, CDCl_3) δ 172.5, 165.8, 165.4, 160.5 (d, $J_{\text{CF}} = 245.8$ Hz), 159.6 (d, $J_{\text{CF}} = 250.0$ Hz), 155.9, 153.9, 140.7 (dd, $J_{\text{CF}} = 2.0, 2.0$ Hz), 140.3 (dd, $J_{\text{CF}} = 8.1, 2.2$ Hz), 135.6 (q, $J_{\text{CF}} = 31.2$ Hz), 133.3, 131.3 (d, $J_{\text{CF}} = 8.9$ Hz), 130.1 (d, $J_{\text{CF}} = 4.8$ Hz), 126.3 (d, $J_{\text{CF}} = 1.3$ Hz), 125.2 (d, $J_{\text{CF}} = 10.3$ Hz), 124.0 (d, $J_{\text{CF}} = 3.2$ Hz), 122.6, 122.8 (q, $J_{\text{CF}} = 273.5$ Hz), 121.3 (d, $J_{\text{CF}} = 17.0$ Hz), 119.7 (q, $J_{\text{CF}} = 4.9$ Hz), 116.4, 115.2 (d, $J_{\text{CF}} = 4.7$ Hz), 114.9 (dd, $J_{\text{CF}} = 3.5$ Hz), 52.4, 38.0, 37.0 (d, $J_{\text{CF}} = 3.7$ Hz), 35.3, 24.5; ^{19}F NMR (376 MHz, CDCl_3) δ -60.9, -114.8, -118.5; HRMS (EI) m/z $[\text{M} + \text{Na}]^+$ Calcd for $\text{C}_{28}\text{H}_{22}\text{F}_5\text{N}_3\text{O}_3\text{Na}$ 566.1479, found 566.1477.

Dimethyl 4',4''-(iminodimethanediyl)bis(3,3'-difluorobiphenyl-2-carboxylate) (19). To a solution of nitrile **11** (1.25 g, 4.57 mmol) in MeOH (15 mL), ammonia (5.5 mL) and freshly prepared Raney Nickel (2.5 g) were added and vigorously stirred for 16 h at rt. Then reaction mixture was filtered through pad of Celite (washing with MeOH), solvent was evaporated and the residue was chromatographed on silica (40–50% EtOAc/hexanes) to give a colorless oil (432.8 mg, 35%). IR (film) 3348, 3003, 2952, 2845, 1736, 1612, 1567, 1511 cm^{-1} ; ^1H NMR (400 MHz, CDCl_3) δ 7.48–7.40 (m, 4H), 7.20–7.04 (m, 8H), 3.92 (s, 4H), 3.72 (s, 6H); ^{13}C NMR (100 MHz, CDCl_3) δ 165.8, 160.9 (d, $J_{\text{CF}} = 245.2$ Hz), 159.6 (d, $J_{\text{CF}} = 250.0$ Hz), 140.9 (dd, $J_{\text{CF}} = 2.3, 2.3$ Hz), 140.0 (d, $J_{\text{CF}} = 8.2, 2.3$ Hz), 131.3 (d, $J_{\text{CF}} = 8.9$ Hz), 130.3 (d, $J_{\text{CF}} = 5.3$ Hz), 126.6 (d, $J_{\text{CF}} = 14.9$ Hz), 125.3 (d, $J_{\text{CF}} = 3.1$ Hz), 123.9 (d, $J_{\text{CF}} = 31.8$ Hz), 115.1 (d, $J_{\text{CF}} = 23.0$ Hz), 114.9 (d, $J_{\text{CF}} = 9.1$ Hz), 52.4, 46.3 (d, $J_{\text{CF}} = 2.7$ Hz); ^{19}F NMR (376 MHz,

CDCl₃) δ -114.8, -118.8; HRMS (ESI-TOF) m/z [M + H]⁺ Calcd for C₃₀H₂₄NO₄F₄ 538.1641, found 538.1636.

■ ASSOCIATED CONTENT

Supporting Information

The Supporting Information is available free of charge on the ACS Publications website at DOI: 10.1021/acs.joc.7b01235.

Detailed experimental procedures for the synthesis of substrates, copies of ¹H, ¹³C and ¹⁹F NMR spectra for all compounds and HPLC data for selected compounds (PDF)

■ AUTHOR INFORMATION

Corresponding Author

*E-mail: michal.michalak@icho.edu.pl.

ORCID

Michał Michalak: 0000-0002-1193-1551

Notes

The authors declare no competing financial interest.

■ ACKNOWLEDGMENTS

This research was supported by Polish Ministry of Science and Higher Education (grant Iuventus Plus IP2012 064172). We are grateful to Dr. Wioletta Kośnik for a helpful and critical discussion during the preparation of the manuscript.

■ REFERENCES

- (1) (a) Wang, J.; Sánchez-Roselló, M.; Aceña, J. L.; del Pozo, C.; Sorochinsky, A. E.; Fustero, S.; Soloshonok, V. A.; Liu, H. *Chem. Rev.* **2014**, *114*, 2432–2506. (b) O'Hagan, D. *J. Fluorine Chem.* **2010**, *131*, 1071–1081.
- (2) Purser, S.; Moore, P. R.; Swallow, S.; Gouverneur, V. *Chem. Soc. Rev.* **2008**, *37*, 320–330.
- (3) (a) Wang, J.; Sánchez-Roselló, M.; Aceña, J. L.; del Pozo, C.; Sorochinsky, A. E.; Fustero, S.; Soloshonok, V. A.; Liu, H. *Chem. Rev.* **2013**, *114*, 2432–2506. (b) Zhou, Y.; Wang, J.; Gu, Z.; Wang, S.; Zhu, W.; Aceña, J. L.; Soloshonok, V. A.; Izawa, K.; Liu, H. *Chem. Rev.* **2016**, *116*, 422–518.
- (4) (a) Böhm, H.-J.; Banner, D.; Bendels, S.; Kansy, M.; Kuhn, B.; Müller, K.; Obst-Sander, U.; Stahl, M. *ChemBioChem* **2004**, *5*, 637–643. (b) Kirk, K. L. *J. Fluorine Chem.* **2006**, *127*, 1013–1029.
- (5) (a) Wu, G.; Wong, Y.; Chen, X.; Ding, Z. *J. Org. Chem.* **1999**, *64*, 3714–3718. (b) Earl, J.; Kirkpatrick, P. *Nat. Rev. Drug Discovery* **2003**, *2*, 97–98.
- (6) (a) Pierce, M. E.; Parsons, R. L.; Radesca, L. A.; Lo, Y. S.; Silverman, S.; Moore, J. R.; Islam, Q.; Choudhury, A.; Fortunak, J. M. D.; Nguyen, D.; Luo, C.; Morgan, S. J.; Davis, W. P.; Confalone, P. N.; Chen, C.-y.; Tillyer, R. D.; Frey, L.; Tan, L.; Xu, F.; Zhao, D.; Thompson, A. S.; Corley, E. G.; Grabowski, E. J. J.; Reamer, R.; Reider, P. J. *J. Org. Chem.* **1998**, *63*, 8536–8543. (b) Chinkov, N.; Warm, A.; Carreira, E. M. *Angew. Chem., Int. Ed.* **2011**, *50*, 2957–2961.
- (7) (a) Liang, T.; Neumann, C. N.; Ritter, T. *Angew. Chem., Int. Ed.* **2013**, *52*, 8214–8264. (b) Campbell, M. G.; Ritter, T. *Chem. Rev.* **2015**, *115*, 612–633. (c) Charpentier, J.; Früh, N.; Togni, A. *Chem. Rev.* **2015**, *115*, 650–682. (d) Liu, X.; Xu, C.; Wang, M.; Liu, Q. *Chem. Rev.* **2015**, *115*, 683–730. (e) Yang, X.; Wu, T.; Phipps, R. J.; Toste, F. D. *Chem. Rev.* **2015**, *115*, 826–870. (f) In *Modern Synthesis Processes and Reactivity of Fluorinated Compounds*; Leroux, F. R., Tressaud, A., Eds.; Elsevier, 2017.
- (8) Nenajdenko, V. *Fluorine in Heterocyclic Chemistry*; Springer International Publishing, 2014; Vol. 2.
- (9) Skrap, Z. *Ber. Dtsch. Chem. Ges.* **1880**, *13*, 2086–2087.
- (10) Doebner, O.; Miller, W. *Ber. Dtsch. Chem. Ges.* **1881**, *14*, 2812–2817.
- (11) Gould, R. G.; Jacobs, W. A. *J. Am. Chem. Soc.* **1939**, *61*, 2890–2895.
- (12) Conrad, M.; Limpach, L. *Ber. Dtsch. Chem. Ges.* **1887**, *20*, 944–948.
- (13) Combes, A. *Bull. Soc. Chim. Fr.* **1883**, *49*, 89.
- (14) Knorr, L. *Justus Liebigs Ann. Chem.* **1886**, *236*, 69–115.
- (15) Niementowski, S. *Ber. Dtsch. Chem. Ges.* **1894**, *27*, 1394–1403.
- (16) (a) Friedlaender, P. *Ber. Dtsch. Chem. Ges.* **1882**, *15*, 2572–2575. (b) Marco-Contelles, J.; Pérez-Mayoral, E.; Samadi, A.; Carreiras, M. d. C.; Soriano, E. *Chem. Rev.* **2009**, *109*, 2652–2671.
- (17) (a) Liu, X.-Y.; Xiao, Y.-P.; Siu, F.-M.; Ni, L.-C.; Chen, Y.; Wang, L.; Che, C.-M. *Org. Biomol. Chem.* **2012**, *10*, 7208–7219. (b) Patil, N. T.; Raut, V. S.; Shinde, V. S.; Gayatri, G.; Sastry, G. N. *Chem. - Eur. J.* **2012**, *18*, 5530–5535. (c) Patil, N. T.; Raut, V. S.; Tella, R. B. *Chem. Commun.* **2013**, *49*, 570–572. (d) Shaikh, A. C.; Ranade, D. S.; Thorat, S.; Maity, A.; Kulkarni, P. P.; Gonnade, R. G.; Munshi, P.; Patil, N. T. *Chem. Commun.* **2015**, *51*, 16115–16118.
- (18) Li, H.; Wang, C.; Huang, H.; Xu, X.; Li, Y. *Tetrahedron Lett.* **2011**, *52*, 1108–1111.
- (19) Li, H.; Xu, X.; Yang, J.; Xie, X.; Huang, H.; Li, Y. *Tetrahedron Lett.* **2011**, *52*, 530–533.
- (20) Patil, N. T.; Raut, V. S. *J. Org. Chem.* **2010**, *75*, 6961–6964.
- (21) Jiang, B.; Si, Y.-G. *J. Org. Chem.* **2002**, *67*, 9449–9451.
- (22) Zhao, B.-C.; Zhang, Q.-Z.; Zhou, W.-Y.; Tao, H.-C.; Li, Z.-G. *RSC Adv.* **2013**, *3*, 13106–13109.
- (23) Wozniak, L.; Staszewska-Krajewska, O.; Michalak, M. *Chem. Commun.* **2015**, *51*, 1933–1936.
- (24) Czerwiński, P.; Molga, E.; Cavallo, L.; Poater, A.; Michalak, M. *Chem. - Eur. J.* **2016**, *22*, 8089–8094.
- (25) Jones, C.; Mills, D. P.; Rose, R. P.; Stasch, A.; Woodul, W. D. *J. Organomet. Chem.* **2010**, *695*, 2410–2417.
- (26) (a) Díez-González, S.; Correa, A.; Cavallo, L.; Nolan, S. P. *Chem. - Eur. J.* **2006**, *12*, 7558–7564. (b) Díez-González, S.; Nolan, S. P. *Angew. Chem., Int. Ed.* **2008**, *47*, 8881–8884.
- (27) van Koten, G.; James, S. L.; Jastrzebski, J. T. B. H. In *Comprehensive Organometallic Chemistry II*; Stone, F. G. A., Wilkinson, G., Eds.; Pergamon: Oxford, 1995.
- (28) (a) Yu, D.; Zhang, Y. *Proc. Natl. Acad. Sci. U. S. A.* **2010**, *107*, 20184–20189. (b) Nelson, D. J.; Nolan, S. P. *Chem. Soc. Rev.* **2013**, *42*, 6723–6753.
- (29) The term “on water”, introduced by Sharpless, refers to a reaction in which one of the substrates is a liquid. In the case when all substrates are solid, it is possible to recreate this effect if they melt under the reaction conditions, creating an organic phase or when they have been melted together before the reaction. In the case of the test reaction, all of the substrates were solid and due to the sensitivity of the NHCCuX complex could not be melted. For this reason, the mixture of substrates was dissolved in a minimum volume of DME and then water was added in order to preserve the unique reactivity Narayan, S.; Muldoon, J.; Finn, M. G.; Fokin, V. V.; Kolb, H. C.; Sharpless, K. B. *Angew. Chem., Int. Ed.* **2005**, *44*, 3275–3279.
- (30) Wang, Y.; Ai, J.; Liu, G.; Geng, M.; Zhang, A. *Org. Biomol. Chem.* **2011**, *9*, 5930–5933.
- (31) Griffiths, G. J.; Warm, A. *Org. Process Res. Dev.* **2016**, *20*, 803–813.
- (32) Aoki, S.; Watanabe, Y.; Sanagawa, M.; Setiawan, A.; Kotoku, N.; Kobayashi, M. *J. Am. Chem. Soc.* **2006**, *128*, 3148–3149.
- (33) (a) Bryce, A.; Ryan, C. J. *Clin. Pharmacol. Ther.* **2012**, *91*, 101–108. (b) Salvador, J. A. R.; Carvalho, J. F. S.; Neves, M. A. C.; Silvestre, S. M.; Leitao, A. J.; Silva, M. M. C.; Sa e Melo, M. L. *Nat. Prod. Rep.* **2013**, *30*, 324–374.
- (34) Czakó, B.; Kürti, L.; Mammoto, A.; Ingber, D. E.; Corey, E. J. *J. Am. Chem. Soc.* **2009**, *131*, 9014–9019.
- (35) (a) Lee, H. M.; Nieto-Oberhuber, C.; Shair, M. D. *J. Am. Chem. Soc.* **2008**, *130*, 16864–16866. (b) Nilson, M. G.; Funk, R. L. *J. Am. Chem. Soc.* **2011**, *133*, 12451–12453. (c) Shenvi, R. A.; Guerrero, C. A.; Shi, J.; Li, C.-C.; Baran, P. S. *J. Am. Chem. Soc.* **2008**, *130*, 7241–7243. (d) Shi, J.; Manolikakes, G.; Yeh, C.-H.; Guerrero, C. A.; Shenvi,

R. A.; Shigehisa, H.; Baran, P. S. *J. Am. Chem. Soc.* **2011**, *133*, 8014–8027.

(36) Yoo, W.-J.; Nguyen, T. V. Q.; Kobayashi, S. *Angew. Chem., Int. Ed.* **2014**, *53*, 10213–10217.

(37) Meanwell, N. A. *J. Med. Chem.* **2011**, *54*, 2529–2591.

(38) Zafrani, Y.; Yeffet, D.; Sod-Moriah, G.; Berliner, A.; Amir, D.; Marciano, D.; Gershonov, E.; Saphier, S. *J. Med. Chem.* **2017**, *60*, 797–804.

(39) (a) Feng, Z.; Min, Q.-Q.; Zhang, X. *Org. Lett.* **2016**, *18*, 44–47. (b) Ge, S.; Chaladaj, W.; Hartwig, J. F. *J. Am. Chem. Soc.* **2014**, *136*, 4149–4152.

(40) Xu, L.; Vacic, D. A. *J. Am. Chem. Soc.* **2016**, *138*, 2536–2539.

(41) (a) Fujikawa, K.; Fujioka, Y.; Kobayashi, A.; Amii, H. *Org. Lett.* **2011**, *13*, 5560–5563. (b) Fier, P. S.; Hartwig, J. F. *J. Am. Chem. Soc.* **2012**, *134*, 5524–5527.

(42) (a) Prakash, G. K. S.; Ganesh, S. K.; Jones, J.-P.; Kulkarni, A.; Masood, K.; Swabeck, J. K.; Olah, G. A. *Angew. Chem., Int. Ed.* **2012**, *51*, 12090–12094. (b) Fujiwara, Y.; Dixon, J. A.; Rodriguez, R. A.; Baxter, R. D.; Dixon, D. D.; Collins, M. R.; Blackmond, D. G.; Baran, P. S. *J. Am. Chem. Soc.* **2012**, *134*, 1494–1497.

(43) Rubic, T.; Lametschwandtner, G.; Jost, S.; Hinteregger, S.; Kund, J.; Carballido-Perrig, N.; Schwarzler, C.; Junt, T.; Voshol, H.; Meingassner, J. G.; Mao, X.; Werner, G.; Rot, A.; Carballido, J. M. *Nat. Immunol.* **2008**, *9*, 1261–1269.

(44) (a) Blakeney, J. S.; Reid, R. C.; Le, G. T.; Fairlie, D. P. *Chem. Rev.* **2007**, *107*, 2960–3041. (b) Congreve, M.; Langmead, C. J.; Mason, J. S.; Marshall, F. H. *J. Med. Chem.* **2011**, *54*, 4283–4311. (c) Blad, C. C.; Tang, C.; Offermanns, S. *Nat. Rev. Drug Discovery* **2012**, *11*, 603–619. (d) de Castro Fonseca, M.; Aguiar, C. J.; da Rocha Franco, J. A.; Gingold, R. N.; Leite, M. F. *Cell Commun. Signaling* **2016**, *14*, 3.

(45) He, W.; Miao, F. J. P.; Lin, D. C. H.; Schwandner, R. T.; Wang, Z.; Gao, J.; Chen, J.-L.; Tian, H.; Ling, L. *Nature* **2004**, *429*, 188–193.

(46) (a) Bhuniya, D.; Umrani, D.; Dave, B.; Salunke, D.; Kukreja, G.; Gundu, J.; Naykodi, M.; Shaikh, N. S.; Shitole, P.; Kurhade, S.; De, S.; Majumdar, S.; Reddy, S. B.; Tambe, S.; Shejul, Y.; Chugh, A.; Palle, V. P.; Mookhtiar, K. A.; Cully, D.; Vacca, J.; Chakravarty, P. K.; Nargund, R. P.; Wright, S. D.; Graziano, M. P.; Singh, S. B.; Roy, S.; Cai, T.-Q. *Bioorg. Med. Chem. Lett.* **2011**, *21*, 3596–3602. (b) Klenc, J.; Lipowska, M.; Taylor, A. T. *Bioorg. Med. Chem. Lett.* **2015**, *25*, 2335–2339.

(47) Sapountzis, I.; Lin, W.; Kofink, C. C.; Despotopoulou, C.; Knochel, P. *Angew. Chem., Int. Ed.* **2005**, *44*, 1654–1658.

(48) Hydrogenation of nitriles catalyzed by Raney nickel often leads to mixtures of primary, secondary and even tertiary amines as a result of side reaction of the primary amine with the imine intermediate: Nishimura, S. In *Handbook Of Heterogeneous Catalytic Hydrogenation For Organic Synthesis*; John Wiley & Sons, 2001.

(49) Santoro, O.; Collado, A.; Slawin, A. M. Z.; Nolan, S. P.; Cazin, C. S. J. *Chem. Commun.* **2013**, *49*, 10483–10485.

(50) Broggi, J.; Díez-González, S.; Petersen, J. L.; Berteina-Raboin, S.; Nolan, S. P.; Agrofoglio, L. A. *Synthesis* **2008**, *2008*, 141–148.

(51) Díez-González, S.; Escudero-Adan, E. C.; Benet-Buchholz, J.; Stevens, E. D.; Slawin, A. M. Z.; Nolan, S. P. *Dalton Trans.* **2010**, *39*, 7595–7606.

(52) Uehling, M. R.; Suess, A. M.; Lalic, G. *J. Am. Chem. Soc.* **2015**, *137*, 1424–1427.

(53) Nolte, C.; Mayer, P.; Straub, B. F. *Angew. Chem., Int. Ed.* **2007**, *46*, 2101–2103.

(54) Díez-González, S.; Scott, N. M.; Nolan, S. P. *Organometallics* **2006**, *25*, 2355–2358.

(55) Duclos, S.; Stoeckli-Evans, H.; Ward, T. R. *Helv. Chim. Acta* **2001**, *84*, 3148–3161.

(56) Boeck, F.; Kribber, T.; Xiao, L.; Hintermann, L. *J. Am. Chem. Soc.* **2011**, *133*, 8138–8141.

(57) Kovács, D.; Kádár, Z.; Mótyán, G.; Schneider, G.; Wölfling, J.; Zupkó, I.; Frank, É. *Steroids* **2012**, *77*, 1075–1085.

(58) Lee, P. H.; Kim, H.; Lee, K.; Kim, M.; Noh, K.; Kim, H.; Seomoon, D. *Angew. Chem., Int. Ed.* **2005**, *44*, 1840–1843.

(59) Petasis, N.; Myslinska, M. US2009247766, 2009.

(60) Zhu, L.; Miao, Z.; Sheng, C.; Yao, J.; Zhuang, C.; Zhang, W. *J. Fluorine Chem.* **2010**, *131*, 800–804.

(61) Patel, M.; Ko, S. S.; McHugh, R. J., Jr; Markwalder, J. A.; Srivastava, A. S.; Cordova, B. C.; Klabe, R. M.; Erickson-Viitanen, S.; Trainor, G. L.; Seitz, S. P. *Bioorg. Med. Chem. Lett.* **1999**, *9*, 2805–2810.

(62) Sohda, T.; Mizuno, K.; Imamiya, E.; Sugiyama, Y.; Fujita, T.; Kawamatsu, Y. *Chem. Pharm. Bull.* **1982**, *30*, 3580–3600.

(63) Ishikawa, S.; Mizutani, T.; Nagase, T.; Sato, N.; Takahashi, H. EP2210880, 2010.

(64) Cheng, J.; Zhai, H.; Bai, J.; Tang, J.; Lv, L.; Sun, B. *Tetrahedron Lett.* **2014**, *55*, 4044–4046.